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SCREENING FOR ANTI-MICROBIAL ACTIVITY 
PRILIMINARY ANTI-MICROBIAL STUDIES 
Methods  
Procedure employed in anti-microbial assay may be divided into broad classification  
                                                       Disc diffusion method 
                                                       Minimum inhibitory concentration method 
DISC DIFFUSION METHOD 86, 87 
In this method, the drug activity is based on measurement of the diameter of zone of 
inhibition surrounding the discs which are placed on the surface of a nutrient medium 
previously inoculated with a culture of suitable microorganisms. Inhibition produced by the test 
compound is compared with that of known standard.  
 
MINIMUM INHIBITORY CONCENTRATION METHOD 
   Minimum inhibitory concentration (MIC) is the lowest concentration of an anti-micro- 
bial that will inhibit the visible growth of a microorganism after overnight incubation. 
Minimum inhibitory concentrations are important in diagnostic laboratories to confirm 
resistance of microorganisms to an antimicrobial agent and also to monitor the activity of new 
antimicrobial agents. A lower MIC is an indication of a better anti-microbial agent. 
 
ANTIBACTERIAL SCREENING BY DISC DIFFUSION METHOD 
Preparation of inoculum 
The inoculum for the experiment was prepared freshly in Muller Hinton broth. Muller 
Hinton broth was prepared by dissolving 0.21gms of muller hinton broth in 10ml of distilled 
water and kept for sterilisation in auto clave for 30 minutes and afterwards the broth and culture 
was transferred to Laminar Air Flow bench.  The sterile inoculation loop was taken and one 
time dipped in the bacterial culture and then it was dipped in the Muller Hinton broth it was 
kept in the B.O.D Incubator at 37oCfor 24hrs.  
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Preparation of sample disc 
      Sample solutions of 100 µg/ml concentration were prepared by dissolving the sample in 
DMSO solvent and the sterile discs were dipped into the sample solution for 20minutes. 
 
List of bacterial strains used 
Six gram-positive bacterial strains, Micrococcus luteus NCIM ( National Collection of 
Industrial Microorganisms) 2169, staphylococcus aureus NCIM 2079, Bacillus subtilis NCIM 
2063, Cornybacterium NCIM 2640, Bacillus lintus NCIM 2018, Staphylococcus albus NCIM 
2178, and six gram-negative bacteria strain, Escherichia Coli  NCIM 2065, Pseudomonas 
aruginosa NCIM 2018, Rhodosporum ruberum NCIM 5128, Vibrio cholera NCIM 1738, 
Salmonella Paratyphii NCIM 2075, Klbsellia pneumonia NCIM 2957 were grown in 
Pharmaceutical Biotechnology Laboratory, KMCH College of pharmacy, Coimbatore. For the 
study, fresh 24hr broth cultures were used. 
 
ANTI-BACTERIAL SCREENING BY 
Kirby-Bauer Method 
38 gms of Muller Hinton agar was dissolved in 1000ml distilled water and 2gms of agar 
was added and kept for sterilisation in auto clave. The Petri plates were cleaned, sterilised and 
marked. Both media and plates were transferred to Laminar Air Flow bench and the medium 
was poured uniformly into the plates while in hot condition and allowed to solidify. The 
bacteria were streaked onto the medium by dipping the sterile swab in the inoculum by 
removing the excess of inoculum by pressing and rotating the swab firmly against the sides of 
the culture tube above the level of liquid. The sterile disc containing the drugs, standard were 
placed on the previously inoculuated surface of the media and kept in the B.O.D Incubator for 
at 37˚C for 24hrs. 
Observations were made for zone inhibition around the tested drugs (100µg/disc) and 
compared with that of standard (Ciprofloxacin 5µg/disc). All the synthesised compounds were 
tested against six Gram-positive and six Gram-negative bacteria and their results were given in 
the table no: 6.1 & 6.2. 
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ANTIFUNGAL SCREENING BY DISC DIFFUSION METHOD 
Preparation of inoculums 
Preparation of inoculums of fungus was carried out by Sabourand’s Dextrose Broth and 
transferred to test tube and kept it for sterilization in autoclave at 1200 C for 15 min. Then added 
culture of each fungal to each tube (this step was carried out in aseptic room near laminar air 
flow) then kept it for incubation in incubator for 24-48 h at 290 C. 
Preparation of sample disc 
      Sample solutions of 100 µg/ml concentration were prepared by dissolving the sample in 
DMSO solvent and the sterile discs were dipped into the sample solution for 20minutes  
 
List of fungal strains used 
Six fungai Candida albicans NCIM 3100, Monococcus purpureus MTCC 1090, Aspergillus 
niger MTCC 1344, Trichophyton rubrum MTCC 3272, Aspergillus fumigates MTCC 1811, 
Aspergillus parasites MTCC 2796 were grown in Pharmaceutical Biotechnology Laboratory, 
KMCH College of pharmacy, Coimbatore. For the study, fresh 24hr broth cultures were used. 
ANTI FUNGAL SCREENING By 
Kirby-Bauer Method 
   Sabourand’s Dextrose agar medium was prepared by dissolving 1 gm of peptone and 4 gm of 
dextrose in 100 ml of distilled water and agar-agar 1-2 gm for solubilisation, then kept it for 
sterilization in autoclave for 1210 C for 15 min. The Petri plates were cleaned, sterilized and 
marked. These medium (Sabourand’s Dextrose agar) were poured into petri-plates under aseptic 
conditions and allowed to solidify. Standardized fungal inoculum was spread uniformly over the 
surface of medium by using a sterile non-absorbent cotton swab and finally the swab was passed 
around the edge of the medium. The inoculated petri plates were closed with the lid and allowed 
to dry at room temperature. The sample impregnated discs and standard discs were placed on the 
inoculated agar medium. All petriplates were incubated at 290C for 24 - 48 hours. After the 
incubation, diameter of zone of inhibition produced by the sample and standard was measured. 
The details are tabulated in table no: 6.3. 
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DISC DIFFUSION METHOD 
 
 
Micro organism                             : Staphylococcus aureus (Gram positive) 
Concentrations of Synthesized compounds   : 100µg/disc 
Standard disc           : Ciprofloxacin 5µg/disc 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 6.1 Activity of compounds against Staphylococcus aureus 
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DISC DIFFUSION METHOD 
 
Micro organism                                             : Escherichia Coli (Gram negative) 
Concentrations of Synthesized compounds   : 100µg/disc 
Standard disc           : Ciprofloxacin 5µg/disc 
 
     
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 6.2 Activity of compounds against Escherichia Coli 
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DISC DIFFUSION METHOD 
 
Micro organism                                                               :         Candida albicans   
Concentrations of synthesized compounds   : 100µg/disc 
Standard disc      : Clotrimazole 5µg/disc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 6.3 Activity of compounds against Candida albicans. 
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Table: 6.1 THE IN-VITRO ANTI-BACTERIAL ACTIVITY (GRAM POSITIVE STRAINS) DATA IN ZONE OF 
INHIBITION (mm) AND PERCENTAGE INHIBITION BY DISC DIFFUSSION METHOD  
 
  
 
S.NO 
 
COMPOUND CODE 
Diameter of zone of inhibition (mm)/pecentage of inhibition 
Micrococcus luteus Staphylococcus aureus Bacillus subtilis Corny bacterium Bacillus lintus Staphylococcus albus 
1 B1P 12(54%) 23(92%) 12(54%) 10(55%) 13(65%) 20(90%) 
2 B1PB 14 (63%) 20(80%) 18(81%) 10(55%) 16(80%) 20(90%) 
3 B1M 15 (68%) 23(92%) 11(50%) 10(55%) - 20(90%) 
4 B1Br - 13(52%) - - - 12(54%) 
5 B12C - 9(36%) - - - - 
6 B14C - - - - - - 
7 B1AZ 12 (54%) 18(72%) 20(90%) 12(66%) 20(100%) 18(81%) 
8 B12N - - - - - - 
9 B14N - 9(36%) 9(40%) - - 9(40%) 
10 B1AP 14 (63%) 18(72%) - - - 16(72%) 
11 B1T 12 (54%) 17(68%) 13(59%) 12(66%) 11(55%) 13(59%) 
12 B1B 14 (63%) 20(80%) 15(68%) 11(61%) 13(65%) 20(90%) 
Std CIPROFLOXACIN 22 25 22 18 20 22 
 DMSO - - - - - - 
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Table: 6.2 THE IN-VITRO ANTI-BACTERIAL ACTIVITY (GRAM NEGATIVE STRAINS) DATA IN 
ZONE OF INHIBITION (mm) AND PERCENTAGE INHIBITION BY DISC DIFFUSSION METHOD  
 
 
 
S.NO 
 
COMPOUND CODE 
Diameter of zone of inhibition (mm) /percentage of inhibition 
Escherichia 
coli 
Pseudomonas 
aruginosa 
Rhodosporum 
ruberum 
Vibrio 
cholera 
Salmonella 
paratyphii 
Klbsellia 
pneumonia 
1 B1P 15(100%) 10(71%) 12(75%) - - 12(75%) 
2 B1PB 14(93%) 12(85%) 12(75%) - 18(90%) 10(62%) 
3 B1M 13(86%) 10(71%) 10(62%) - - 10(62%) 
4 B1Br 10(66%) 9(64%) 9(56%) - - 10(62%) 
5 B12C 7(46%) - - - - 8(50%) 
6 B14C 10(66%) 9(64%) 8(50%) - - - 
7 B1AZ 12(80%) 10(71%) 10(62%) 11(55%) - - 
8 B12N 8(53%) - - - - - 
9 B14N 7(46%) 9(64%) - - - 8(50%) 
10 B1AP 9(60%) 10(71%) 11(68%) - - - 
11 B1T 7(46%) - - - - 10(62%) 
12 B1B 15(100%) 12(85%) 14(87%) 10(50%) - 10(62%) 
Std CIPROFLOXACIN 15 14 16 20 20 16 
 DMSO - - - - - - 
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Table: 6.3 THE IN-VITRO ANTI-FUNGAL ACTIVITY DATA IN ZONE OF INHIBITION (mm) AND 
PERCENTAGE INHIBITION BY DISC DIFFUSSION METHOD 
 
 
S.N
O 
 
COMPOUND CODE 
Diameter of zone of inhibition (mm)/ percentage of inhibition 
Candida 
albicans 
Monococcus 
purpureus 
Aspergillus 
niger 
Trichophyton 
rubrum 
Aspergillus fumigates Aspergillus parasites 
1 B1P 10(50%) 7(53%) - - - - 
2 B1PB - - - - 9(39%) 13(54%) 
3 B1M - - - - - - 
4 B1Br 10(50%) - 9(47%) - 14(60%) 16(66%) 
5 B12C - - 13(68%) - 15(65%) 12(50%) 
6 B14C 10(50%) - 12(63%) - - - 
7 B1AZ - 9(69%) - 8(53%) 9(39%) 10(41%) 
8 B12N 12(60%) - 14(73%) - 15(65%) 17(70%) 
9 B14N 14(70%) - 13(68%) - 16(69%) 16(66%) 
10 B1AP - - - - - - 
11 B1T - - - - - - 
12 B1B - 9(69%) 9(47%) 8(53%) 12(52%) - 
Std CLO-TRIMAZOLE 20 13 19 15 23 24 
 DMSO - - - - - - 
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Fig: 6.4 The in-vitro anti-bacterial activity (gram positive strains) by disc diffusion method 
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Fig: 6.5The in-vitro anti-bacterial activity (gram negative strains) by disc diffusion method 
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Fig:6.6 The in-vitro anti-fungal activity by disc diffusion method 
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MINIMUM INHIBITORY CONCENTRATION (MIC) 88 
 MIC is the lowest concentration of an anti-microbial agent that will inhibit the visible 
growth of a microorganism. Minimum inhibitory concentrations are important in diagnostic 
laboratories to confirm resistance of microorganisms to an anti-microbial agent and also to 
monitor the activity of new anti-microbial agents. The activity of the drug is based on inhibition 
of microbial growth as indicated by measurement of turbidity of a suspension of a suitable 
microorganism in a fluid medium to which graded amount of test compound have been added. 
These changes in turbidity were compared with that of a reference compound. 
 
Procedure for determination of minimum inhibitory concentration for 
synthesized compounds against bacteria by serial dilution method 
The serial dilution of compound solutions were made from the stock (1000 µg/ml) by using 
Muller Hinton broth using the method described below. 
 The tubes were labelled 1 to 8 and 1 ml of Muller Hinton broth was added to the first 5 
tubes and 8th tube, and then added 0.5 ml Muller Hinton broth to 6th and 7th tubes. 
 1 ml of different synthesized compounds was added to the 1st tube, mixed and transferred 
1 ml serially up to tube 6. Mixed and transferred 0.5 ml to the 7th tube so that each tube, 
1 to 7 contained 1 ml diluted extracts. The 8th tube served as the control. 
 With a standardized micro pipette, added a drop of the diluted broth culture 
approximately 0.01 ml of the test organism to all tubes, including the control, gently 
mixed and incubated at 37 0 C for 18 hrs. 
 After incubation the turbidity was observed. The highest dilution of particular compounds 
showing no turbidity and recorded. This was taken as the end point, and this dilution was 
considered to contain the concentration of drug equivalent to MIC [149]. The details are 
tabulated in Table no: 6.4 & 6.5 
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Procedure for determination of minimum inhibitory concentration for 
synthesized compounds against fungi by serial dilution method 
The serial dilution of compound solutions were made from the stock (1000 µg/ml) by using 
Sabourand’s dextrose broth using the method described below. 
 The tubes were labelled 1 to 8 and 1 ml of Sabourand’s dextrose broth was added to the 
first 5 tubes and 8th tube, and then added 0.5 ml Muller Hinton broth to 6th and 7th 
tubes. 
 1 ml of different synthesized compounds was added to the 1st tube, mixed and transferred 
1 ml serially up to tube 6. Mixed and transferred 0.5 ml to the 7th tube so that each tube, 
1 to 7 contained 1 ml diluted extracts. The 8th tube served as the control. 
 With a standardized micro pipette, added a drop of the diluted broth culture 
approximately 0.01ml of the test organism to all tubes, including the control, gently 
mixed and incubated at 270 C for 24 - 48 hrs. 
 The highest dilution of particular compounds showing no turbidity was observed and 
recorded. This was taken as the end point, and this dilution was considered to contain the 
concentration of drug equivalent to MIC.[150] The details are tabulated in Table no:6.6 
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Table: 6.4 THE IN-VITRO ANTI-BACTERIAL ACTIVITY (GRAM POSITIVE STRAINS) DATA IN 
MINIMUM INHIBITORY CONCENTRATION 
 
S.NO 
 
COMPOUND CODE 
Minimum inhibitory concentration (µg/ml) 
Micrococcus luteus Staphylococcus aureus Bacillus subtilis Corny bacterium Bacillus lintus Staphylococcus albus 
1 B1P 25 6.25 25 25 25 6.25 
2 B1PB 12.5 6.25 12.5 25 12.5 6.25 
3 B1M 12.5 6.25 25 25 NT 6.25 
4 B1Br NT 25 NT NT NT 25 
5 B12C NT 25 NT NT NT NT 
6 B14C NT NT NT NT NT NT 
7 B1AZ 25 25 6.25 12.5 6.25 12.5 
8 B12N NT NT NT NT NT NT 
9 B14N NT 25 12.5 NT NT 25 
10 B1AP 12.5 12.5 NT NT NT 12.5 
11 B1T 25 12.5 25 12.5 25 25 
12 B1B 12.5 6.25 12.5 12.5 25 6.25 
Std CIPROFLOXACIN 22 25 22 18 20 22 
 DMSO - - - - - - 
         
   NT=NOT TESTED          
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Table: 6.5 THE IN-VITRO ANTI-BACTERIAL ACTIVITY (GRAM NEGATIVE STRAINS) DATA IN 
MINIMUM INHIBITORY CONCENTRATION 
 
 
NT= NOT TESTED 
 
 
S.NO 
 
COMPOUND CODE 
Minimum inhibitory concentration (µg/ml) 
Escherichia 
coli 
Pseudomonas 
aruginosa 
Rhodosporum 
ruberum 
Vibrio 
cholera 
Salmonella 
paratyphii 
Klbsellia 
pneumonia 
1 B1P 6.25 12.5 12.5 NT NT 12.5 
2 B1PB 6.25 12.5 12.5 NT 6.25 12.5 
3 B1M 6.25 12.5 25 NT NT 25 
4 B1Br 12.5 12.5 25 NT NT 12.5 
5 B12C 25 NT NT NT NT 25 
6 B14C 25 12.5 25 NT NT NT 
7 B1AZ 12.5 25 12.5 25 NT NT 
8 B12N 25 NT NT NT NT NT 
9 B14N 25 12.5 NT NT NT 25 
10 B1AP 25 12.5 12.5 NT NT NT 
11 B1T 25 NT NT NT NT 12.5 
12 B1B 6.25 6.25 6.25 25 NT 12.5 
Std CIPROFLOXACIN 15 14 16 20 20 16 
 DMSO - - - - - - 
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Table: 6.6 THE IN-VITRO ANTIFUNGAL ACTIVITY DATA IN MINIMUM INHIBITORY 
CONCENTRATION 
 
NT=NOT TESTED 
S.N
O 
COMPOUND  
CODE 
Minimum inhibitory concentration (µg/ml) 
Candida 
albicans
Monococcus 
purpureus 
Aspergillus 
niger 
Trychophyton  
rubrum 
Aspergillus 
fumigates 
Aspergillus 
parasites 
1 B1P 25 25 NT NT NT NT 
2 B1PB NT NT NT NT 25 25 
3 B1M NT NT NT NT NT NT 
4 B1Br 25 NT 12.5 NT 12.5 25 
5 B12C NT NT 12.5 NT 12.5 25 
6 B14C 25 NT 6.25 NT NT NT 
7 B1AZ NT 12.5 NT 25 25 25 
8 B12N 12.5 NT 12.5 NT 12.5 12.5 
9 B14N 12.5 NT 25 NT 12.5 12.5 
10 B1AP NT NT NT NT NT NT 
11 B1T NT NT NT NT NT NT 
12 B1B NT 12.5 25 25 25 NT 
Std CLO-TRIMAZOLE  20 13 19 15 23 24 
 DMSO - - - - - - 
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IN-VITRO ANTI-OXIDANT SCREENING OF SYNTHESIZED 
COMPOUNDS89 
¾ In-vitro anti-oxidant screening of synthesized compounds were done by using three 
methods  
9 DPPH method 
9 FRAP method  
9 ABTS method 
Determination of DPPH (1-1-diphenyl 2-picryl hydrazyl) radical-
scavenging activity: 
 
Procedure: 
The free radical-scavenging activity of the synthesized compounds was measured in 
terms of hydrogen donating or radical-scavenging ability using the stable radical DPPH. 0.1 
mM solution of DPPH in ethanol was prepared and 1.0 ml of this solution was added to 3.0 
ml of extract solution in methanol at different concentrations (0.1–5 mg/ml). Thirty minutes 
later, the absorbance was measured at 517 nm. Ascorbic acid was used as the reference 
compound. Lower absorbance of the reaction mixture indicated higher free radical-
scavenging activity. Radical scavenging activity was expressed as the inhibition percentage 
of free radical by the sample and was calculated using the following formula: 
 
 
Where A0 was the absorbance of the control (blank, without compounds) and At was the 
absorbance in the presence of the compounds. All the tests were performed in triplicate and 
the graph was plotted with the mean values. 
Ferric reducing antioxidant power (FRAP) assay: 
FRAP assay is based on the ability of anti-oxidants to reduce Fe3+ to Fe2+ in the 
presence of 2,4,6-tri(2-pyridyl)- s-triazine (TPTZ), forming an intense blue Fe2+-TPTZ 
complex with an absorption maximum at 593 nm. This reaction is pH-dependent (optimum 
pH 3.6). The absorbance decrease is proportional to the anti-oxidant content (Benzie and 
Strain, 1996). 0.2 ml of the compound is added to 3.8 ml of FRAP reagent (10 parts of 300 
% inhibition= (A0 - At)/ A0 ×100 
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mM sodium acetate buffer at pH 3.6, 1 part of 10.0 mM TPTZ solution and 1 part of 20.0 
mM FeCl3. 6H2O solution) and the reaction mixture is incubated at 37°C for 30 min and the 
increase in absorbance at 593 nm is measured. FeSO4 is used for calibration. The antioxidant 
capacity based on the ability to reduce ferric ions of sample is calculated from the linear 
calibration curve and expressed as mmol FeSO4 equivalents per gram of sample. BHT, BHA, 
ascorbic acid, quercetin, catechin or trolox can be used as a positive control. 
 
ABTS radical scavenging assay:  
The ABTS assay was employed to measure the anti-oxidant activity of the 
derivatives. ABTS was dissolved in de-ionized water to 7 mM concentration, and potassium 
persulphate added to a concentration of 2.45 mM. The reaction mixture was left to stand at 
room temperature overnight (12–16 h) in the dark before usage. 0.5 ml of derivatives were 
diluted with 0.3 ml ABTS solution and made up to the volume with methanol. Absorbance 
was measured spectrophotometrically at 745 nm. 
The assay was performed at least in triplicates. Fresh stocks of ABTS solution were 
prepared every five days due to self-degradation of the radical. The assay was first carried out 
on Ascorbic acid, which served as a standard. The percentage of inhibition was measured by 
the following formula: 
 
Where A0 was the absorbance of the control (blank, without compounds) and At was the 
Absorbance in the presence of the compounds. All the tests were performed in triplicate and 
the graph was plotted with the mean values. 
 
 
 
 
 
 
% inhibition= (A0 - At)/ A0 
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Table: 6.7 DPPH METHOD 
S.No Compound % Inhibition EC50 
25µg 50 µg 75 µg 100 µg 
1 B1P      24.56 
 
36.48 48.21 64.64 77.78 
2 B1PB 49.76 60.33 80.45 88.53 25.12 
3 B1M 28.93 35.39 47.22 59.22 79.41 
4 B1Br 53.73 64.98 84.76 92.77 23.58 
5 B12C 51.74 62.83 82.76 90.44 24.15 
6 B14C 50.43 61.83 81.99 89.02 25.13 
7 B1AZ        19.78 28.68 38.43 50.12 99.76 
8 B12N 55.67 66.92 86.60 95.83 22.45 
9 B14N 54.56 65.87 85.12 93.67 22.91 
10 B1AP 39.36 67.28 69.45 70.88 31.75 
11 B1T 22.46 29.76 34.87 56.67 88.23 
12 B1B 20.567 29.78 39.88 55.97 89.33 
Std Ascorbic acid 56.7 68.94 89 96 22.04 
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ANTIOXIDANT ACTIVITY OF COMPOUNDS B1P, B1PB, B1M, B1Br, B12C, B14C, 
B1AZ, B12N, B14N, B1AP, B1T, B1B AND ASCORBIC ACID: 
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Table: 6.8 FRAP METHOD 
S.No Compound Absorbance 
R2 
25 µg 50 µg 75 µg 100 µg 
1 B1P 1.97 1.61 1.03 0.91 
 
0.949 
2 B1PB 3.95 3.92 3.9 3.87 0.9841 
3 B1M 3.71 3.42 3.24 3.04 
 
0.988 
4 B1Br 3.86 3.72 3.39 3.47 0.788 
5 B12C 3.97 3.88 3.83 3.84 0.793 
6 B14C 3.89     3.7 3.66 3.66 
 
0.734 
7 B1AZ 3.83 3.79 3.53 3.54 
 
0.885 
8 B12N 3.98      3.89 3.84 3.85 
 
0.793 
9 B14N 3.96      3.87 3.82 3.83 
 
0.793 
10 B1AP 3.87 3.88 3.86 3.84 0.691 
11 B1T 3.91     3.97 3.92 3.91 0.050 
12 B1B 3.98         3.89 3.84 3.85 0.793 
Std Ferrous 
sulphate  
3.45         2.85 2.35 1.89 
 
0.996 
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ANTIOXIDANT ACTIVITY OF COMPOUNDS B1P, B1PB, B1M, B1Br, B12C, B14C, 
B1AZ, B12N, B14N, B1AP, B1T, B1B AND FERROUS SULPHATE: 
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Table: 6.9 ABTS METHOD 
S.No Compound % Inhibition EC50
25 µg 50 µg 75 µg        100 µg 
1 B1P 50.76 61.33 81.45 87.53 24.62 
2 B1PB 24.93 36.39 48.22 60.22 77.76 
3 B1M 21.67 30.78       40.88 56.97 87.76 
4 B1Br 54.73 65.98 85.763 92.77 22.83 
5 B12C 56.67 67.92       87.63 94.83 22.05 
6 B14C 55.56 66.87       86.12 93.87 22.49 
7 B1AZ        20.78 29.68 39.43 51.12 97.80 
8 B12N 52.74 63.83 83.76 91.44 23.70 
9 B14N 51.43 62.83 82.99 88.02 24.30 
10 B1AP 40.36 68.28      70.45 71.88 30.97 
11           B1T 26.46 30.76       35.87 57.67 86.70 
12 B1B      25.56 
 
37.48 49.21 65.64 76.20 
Std Ascorbic acid 58.77 69.94 88.94 97 21.55 
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ANTIOXIDANT ACTIVITY OF COMPOUNDS B1P, B1PB, B1M, B1Br, B12C, B14C, 
B1AZ, B12N, B14N, B1AP, B1T, B1B AND ASCORBIC ACID: 
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IN-VITRO CYTOTOXICITY SCREENING BY MTT ASSAY90, 91 
The mouse embryonic fibroblasts cell line (NIH 3T3) was obtained from National 
Centre for Cell Science (NCCS), Pune, and grown in Dulbeccos modified Eagles medium 
containing 10% fetal bovine serum (FBS). All cells were maintained at 370C, 5% CO2, 95% 
air and 100% relative humidity. Maintenance cultures were passaged weekly, and the culture 
medium was changed twice a week. 
Cell treatment procedure 
 The monolayer cells were detached with trypsin-ethylenediaminetetraacetic acid 
(EDTA) to make single cell suspensions and viable cells were counted using a 
hemocytometer and diluted with medium with 5% FBS to give final density of 1x105 
cells/ml. one hundred microlitres per well of cell suspension were seeded into 96-well plates 
at plating density of 10,000 cells/well and incubated to allow for cell attachment at 370C, 5% 
CO2, 95% air and 100% relative humidity. After 24 h the cells were treated with serial 
concentrations of the extracts and fractions. They were initially dissolved in neat 
dimethylsulfoxide (DMSO) and further diluted in serum free medium to produce five 
concentrations. One hundred microlitres per well of each concentration was added to plates to 
obtain final concentrations of 100, 50, 25, 12.5 and 6.25 µM. The final volume in each well 
was 200 µl and the plates were incubated at 370C, 5% CO2, 95% air and 100% relative 
humidity for 48h. The medium containing without samples were served as control. Triplicate 
was maintained for all concentrations. 
MTT assay 
 MTT is a yellow water soluble tetrazolium salt. A mitochondrial enzyme in living 
cells, succinate-dehydrogenase, cleaves the tetrazolium ring, converting the MTT to an 
insoluble purple formazan. Therefore, the amount of formazan produced is directly 
proportional to the number of viable cells. 
 After 48h of incubation, 15µl of MTT (5mg/ml) in phosphate buffered saline (PBS) 
was added to each well and incubated at 370C for 4h. The medium with MTT was then 
flicked off and the formed formazan crystals were solubilised in 100µl of DMSO and then 
measured the absorbance at 570 nm using micro plate reader. The % cell inhibition was 
determined using the following formula.  
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% cell Inhibition = 100- Abs (sample)/Abs (control) x100.  
Nonlinear regression graph was plotted between % Cell inhibition and Log10 
concentration and IC50 was determined using GraphPad Prism software.    
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Table: 6.10 IC50 VALUES OF COMPOUND  
S .No Compound code  Concentration(µM) Percentage of Cell Inhibition(%) 
IC50 
Values(µM)  
1 B1P 
0.1 0.384732 
26.1 
1 3.888274 
10 37.83391 
100 89.31923 
2 B1PB 
0.1 0.678733 
15.34 
 
1 4.298643 
10 34.38914 
100 94.79638 
3 B1AZ 
0.1 2.941176 
20.24 
1 4.524887 
10 28.28054 
100 89.14027 
4 B14C 
0.1 1.58371 
10.95 
1 6.561086 
10 46.15385 
100 97.28507 
 
5 
 
 
B1T 
0.1 1.58371 
14.88 
1 8.144796 
10 35.29412 
100 95.70136 
6 B1B 
0.1 3.61991 
>100 
 
1 6.334842 
10 12.21719 
100 23.07692 
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PHOTOGRAPHS OF MOUSE EMBRYONIC FIBROBLASTS CELL 
LINE (NIH 3T3) INHIBITION BY THE COMPOUND (0.1 µM -100 µM) 
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 Compound B1AZ 
              
                             
                        
Fig: 6.9 
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7.1 CHEMISTRY 
In the present work 12 different N-Mannich bases were synthesised in 4 steps. 
Step: 1   
6-bromobenzo[d]thiazol-2-amine has been synthesized by precooled solution of 4-
bromoaniline and ammonium thiocyanate in glacial acetic acid were stirred, to this mixture 
add bromine in glacial acetic acid for cyclization to form 6-bromobenzo[d]thiazol-2-amine. 
Step: 2   
Ethyl [2-(6-bromo-1,3-benzothiazol-2-yl) hydraziny lidene](cyano)acetate was 
synthesized by coupling diazonium salt with ethylcyanoacetate in presence of sodium 
acetate. The diazonium salt of 6-bromobenzo[d]thiazol-2-amine was synthesized by 
diazotization of 6-bromobenzo[d]thiazol-2-amine with sodium nitrite in concentrated 
hydrochloric acid at 0-5 ˚C. 
Step: 3 
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2,4-dihydro-3H-
pyrazol-3-one was synthesized by cyclising ethyl[2-(6-bromo-1,3-benzothiazol-2-yl) 
hydraziny lidene](cyano)acetate with hydrazine hydrate using ethanol as solvent. 
Step: 4 
N-Mannich bases of 5-amino-4-[2-(6-bromo-1, 3-benzothiazol-2-yl)hydrazinyl-
idene]-2,4-dihydro-3H-pyrazol-3-one were synthesized by refluxing 5-amino-4-[2-(6-
bromo-1, 3-benzothiazol-2-yl)hydrazinylidene]-2,4-dihydro-3H-pyrazol-3-one with 12 
different aromatic amines  and 90% formaldehyde using ethanol as solvent.  
The yield of the synthesised compounds was found to be in the range of 57-95%. The 
Purity of all the newly synthesized compounds were checked by melting point, TLC 
analysis and the structures were confirmed by UV, IR, NMR and MASS spectral data. The 
physicochemical data and analytical data’s were given in the table no: 5.2, 5.3, 5.4&5.5. 
 
 
 
RESULTS AND DISCUSSION 
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7.2 DETERMINATION OF PHYSICOCHEMICAL PROPERTIES OF   
SYNTHESIZED COMPOUNDS 
7.2.1 MELTING POINT ANALYSIS  
Melting points of all the newly synthesised compounds were checked and uncorrected 
and the values were given in table no: 5.2&5.4. 
7.2.2 THIN LAYER CHROMATOGRAPHY ANALYSIS 
The reaction time and purity of the compounds were determined by running TLC and a 
single spot was obtained. Rf Values of all the newly synthesised compounds were 
determined and given in table no: 5.2&5.4. 
7.2.3 SOLUBILITY 
Solubility was checked for all the newly synthesised compounds and found that all the 
compounds were soluble in semi polar solvent. 
 
7.3 CHARACTERIZATION OF SYNTHESISED COMPOUNDS 
7.3.1 INFRARED SPECTRAL ANALYSIS 
The structures of intermediates (BTZ) confirmed by the presence of characteristic peaks 
in the region 3573.45cm-1, 1663.3 cm-1, 669.17 cm-1 associated for –NH2, C=N-, C-S-C 
stretching respectively. The compound BTZE confirmed by the stretching of ester group in 
the region 1702.84cm-1 for keto of acetyl group. The compound BTZP confirmed the 
presence of –NH2 and –NH- groups by the peaks at 3385.42 cm-1 and 3385cm-1 respectively 
and also showed the disappearance of the characteristic bands of the acetyl carbonyl group 
and carboxylic acid ester. 
All the N-Mannich derivative compounds showed the characteristic peaks in the region 
3372.82cm-1 for associated NH of amines, 840- 790 cm-1 for Ar, CH=CH stretching, 1640-
1620 cm-1 and 1600-1400cm-1for C=O stretching. Compound B12N containing NO2 group 
showed absorption bands at 1550-1500, for the N=O stretching. The peak at 771 cm-1 could 
be assigned to C-Cl stretching in the compound B12C. Presence of hydroxyl group was 
confirmed by the appearance of peak at 1165.76 cm-1 in the compound B1P. Presence of 
carboxylic acid group was confirmed by the appearance of peak at Presence of hydroxyl 
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group was confirmed by the appearance of broad peak at 3127.01cm-1 in the compound 
B1PB. 
 
7.3.2 NUCLEAR MAGNETIC RESONANCE SPECTRAL ANALYSIS 
The structures of the twelve new compounds (BTZE, BTZP, B1P, B1PB, B1M, B1Br, 
B12C, B14C, B1AZ, B12N, B14N, B1AP, B1T and B1B) were confirmed by 1H-NMR 
spectra. The 1H-NMR spectra of BTZE showed the presence of the peaks for the ethyl 
group, while the pyrazolinone –NH2 proton signal appeared at δ 6.63ppm. All the 
synthesized  compounds showed multiplets in the range δ 7.5-8.04 for the protons of 
aromatic ring and a doublet at δ 4.5 which may be assigned to –CH2– linkage. The spectrum 
of B1P revealed a singlet at δ 9.1ppm which may be assigned to -OH proton. The spectrum 
of B1M revealed a singlet at δ 3.3ppm which may be assigned to –OCH3 protons. 
 
7.3.3 MASS SPECTRAL ANALYSIS 
Electron impact mass spectral analysis was carried out on four randomly selected 
compounds B1T, B1AZ, B1B, and B14C. Mass spectrums of the compounds were in full 
agreement with their molecular weights. 
 
7.4 BIOLOGICAL EVALUATION 
7.4.1 ANTIMICROBIAL STUDIES 
All the newly synthesised compounds at 100µg/disc were screened for their preliminary 
anti-microbial activity against six gram positive bacteria strains, six gram negative bacteria 
stains and six fungi strains by disc diffusion method using muller hinton agar media for 
bacteria and potato dextrose agar media for fungi, and determination of Minimum Inhibitory 
Concentration (MIC) for selective synthesized compounds was done by 2 fold serial dilution 
method muller hinton broth for bacteria and potato dextrose broth for fungal. 
 
ANTI BACTERIAL ACTIVITY 
PRELIMINARY ANTI-BACTERIAL SCREENING BY DISC DIFFUSION METHOD  
       Muller Hinton agar media was used for screening anti-bacterial activity of synthesized 
compound. Reference standard Ciprofloxacin (5µg/disc), negative control DMSO 
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(DiMethyl Sulfoxide) and synthesized compounds (100µg/disc) were used. Observations 
were made for zone inhibition around the tested drugs and compared with that of reference 
standard. The bacterial zone of inhibition values are given in the table no: 6.1&6.2. The 
result of anti-bacterial activity showed most of the synthesized compounds were moderate to 
significant activity against streptococcus aureus and streptococcus albus (gram positive 
strain) at 100µg/disc compare with that of standard ciprofloxacin 5µg/disc concentration 
level. Especially the substitution of electron donating group attached at the para position of 
N-methyl benzenamine ring imparted significant gram positive as well as gram negative 
anti-bacterial activity to the resulting N-mannich base containing pyrazolone derivatives 
(B1P, B1M, B1AZ, B1AP, B1T and B1B) compared with electron withdrawing group 
attached at the para position of N-methyl benzenamine ring (B1Br, B12C, B14C, B12N, 
B14N). Particularly, the 2nd position of pyrazolone ring containing bulky group link through 
–CH2-NH- bridge (B1AZ and B1B) showed anti-bacterial activity against all tested gram 
positive and gram negative strains at 100µg/disc level.  On the other hand, the presence of 
electron withdrawing group attached at the para position of N-methyl benzenamine ring 
display poor or loss of anti-bacterial activity against both gram positive and gram negative 
bacterial strains except the synthesized compound B1PB. All the synthesized compounds 
showed moderate to significant activity towards E.coli(gram negative bacteria), especially 
the compound B1P and B1B at 100µg/disc showed equal anti-bacterial activity as that of 
standard ciprofloxacin at 5µg/disc concentration level. All the synthesised compounds 
completely devoid activity against vibrio cholera and salmonella paratyphii (gram negative 
bacteria) except the compound B1PB, B1AZ and B1B. 
  
MINIMUM INHIBITORY CONCENTRATION SCREENING BY 2-FOLD 
DILUTION METHOD  
 Based on the preliminary anti bacterial activity screening result, active compounds were 
selected for determining minimum inhibitory concentration (MIC) by 2-fold serial dilution 
method. Muller Hinton broth media was used for determining MIC value of synthesized 
compound. Series of 10-15 dilutions to final concentrations of 100-1.56μg/ml are prepared. 
     The MIC of all the synthesised compounds was found at 6.25µg/ml, 12.5µg/ml, 25µg/ml, 
50µg/ml concentration levels for tested gram positive and gram negative strains. The 
minimum inhibitory concentration values are given in table no: 6.4&6.5 
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ANTI FUNGAL ACTIVITY 
PRELIMINARY ANTI-FUNGAL SCREENING BY DISC DIFFUSION METHOD  
           The result of anti-fungal activity showed that the synthesised compound 100µg/disc 
were  poor or devoid anti fungal activity for most of the tested fungal strains compare to the 
standard clo-trimozole at 5µg/disc concentration level. The synthesized compounds(B1PB, 
B1Br, B12C, B12N and B14N), substitution of electron withdrawing group  attached at the 
para position of N-methyl benzenamine ring imparted moderate anti-fungal activity, 
particularly aspergillus niger, aspergillus fumigates, and aspergillus parasites to the resulting 
N-mannich base containing pyrazolone derivatives. On the other hand, the synthesized 
compound B1AZ and B1B showed moderate activity against most of the tested fungal 
strains. The fungal zone of inhibition value is given in the table no: 6.3. 
 
MINIMUM INHIBITORY CONCENTRATION SCREENING BY 2-FOLD 
DILUTION METHOD  
 Based on the preliminary anti-fungal activity screening result, active compounds were 
selected for determining minimum inhibitory concentration (MIC) by 2-fold serial dilution 
method. Sabourand’s dextrose broth media was used for determining MIC value of 
synthesized compound. Series of 10-15 dilutions to final concentrations of 100-1.56μg/ml 
are prepared. 
        The MIC of all the synthesised compounds was found at 6.25µg/ml, 12.5µg/ml, 25 
µg/ml, 50µg/ml concentration levels for tested fungal strains. The minimum inhibitory 
concentration values are given in table no: 6.6. 
7.4.2 IN-VITRO ANTI OXIDANT ACTIVITIES  
All newly synthesized compounds were screened for in-vitro anti-oxidant activity by 
DPPH, FRAP and ABTS assay method at the concentration of 25µg/ml, 50µg/ml, 75µg/ml 
and 100µg/ml.  DMSO used as a solvent, ascorbic acid used as a standard for DPPH and 
ABTS, ferrous sulphate is used as a standard for FRAP method.   
DPPH  
The result of in-vitro anti-oxidant activity by DPPH method indicates that among the 
screened compounds, compound B12N, B14N, B1Br, B12C, B1PB, B14C and B1AP have 
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significant anti-oxidant activity with EC50 value 22.45, 22.9, 23.58, 24.15, 25.12, 25.13 and 
31.75 respectively. The other synthesized compounds showed mild anti-oxidant activity. 
The DPPH in-vitro anti-oxidant assay method result review that the synthesized compounds 
containing substitution of electron with drawing group attached at the para position of N-
methyl benzenamine ring imparted significant anti-oxidant property to the resulting N-
mannich base containing pyrazolone derivatives (B12N, B14N, B1Br, B12C, B1PB, B14C 
and B1AP). The highest anti-oxidant activity due to the compound with high lipophilic 
value, lowest electron withdrawing power, highly polarisability. The percentage inhibition 
values were given in the table no: 6.7. 
FRAP 
 Among the synthesised derivatives B1P, B1PB, B1M, and B1AZ are having the R2 
value of 0.949, 0.984, 0.988 and 0.885 near to the standard ferrous sulphate value of 0.996 
indicating that compounds showed good anti-oxidant activity. The R2 values were given in 
the table no: 6.8. 
ABTS 
The result of in-vitro anti-oxidant activity by ABTS method shows that among the 
screened compounds, compound B12C, B14C, B1Br, B12N, B14N, B1P and B1AP have 
significant anti-oxidant activity with EC50 value 22.05, 22.49, 22.83, 23.70, 24.30, 24.62 and 
30.97 respectively. The other synthesized compounds showed mild anti-oxidant activity. 
The ABTS in-vitro anti-oxidant assay method review that the synthesized compounds 
containing substitution of electron with drawing group attached at the para position of N-
methyl benzenamine ring imparted significant anti-oxidant property to the resulting N-
mannich base containing pyrazolone derivatives (B12C, B14C, B1Br, B12N, B14N, B1P 
and B1AP). The percentage inhibition values were given in the table no: 6.9. 
 
7.4.3 IN-VITRO CYTOTOXIC ACTIVITY 
Six of the newly synthesized compounds (B1P, B1PB, B14C, B1AZ, B1T, B1B) 
were screened for in vitro cytotoxic activity against mouse embryonic fibroblasts cell line 
(NIH 3T3) by MTT assay in DMSO and their IC50 values are 26.µM, 15.34µM, 10.95µM, 
20.24 µM, 14.88 µM, >100µM respectively. Among the tested compounds B1B showed least 
cytotoxic activity. The IC50 values were given in the table no: 6.10. 
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I. SUMMARY 
8.1 EXPERIMENTAL 
   In the present work twelve title compounds were synthesised by subject 5-amino-4-[2-(6-
bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2,4-dihydro-3H-pyrazol-3-one (BTZP) to 
mannich reaction with 12 different amines. The intermediate 5-amino-4-[2-(6-bromo-1,3-
benzothiazol-2-yl)hydrazinylidene]-2,4-dihydro-3H-pyrazol-3-one(BTZP) was synthesized 
from ethyl[2-(6-bromo-1,3-benzothiazol-2-yl) hydraziny lidene](cyano)acetate (BTZE) by 
cyclising  with hydrazine hydrate. Ethyl[2-(6-bromo-1,3-benzothiazol-2-yl) hydraziny 
lidene](cyano) acetate was synthesized by coupling through diazonium salts of 6-
bromobenzo[d]thiazol-2-amine with ethylcyanoacetate. The compound diazonium salts of 6-
bromobenzo [d]thiazol-2-amine was formed by reacting 6-bromobenzo[d]thiazol-2-amine 
(BTZ) with sodium nitrite in concentrated hydrochloric acid, which in turn was synthssized 
from 4-bromo aniline and thiourea. The yield was found to be 55-75% in all the stage.  
 Most of the newly synthesized compounds were found to be soluble in semi polar 
solvents.  Thin layer chromatography was used to confirm the reaction time and purity of 
the compounds synthesized. Melting point was determined by one end open glass capillary 
tubes and was uncorrected. The UV spectrum values observed between 400-800nm and IR 
spectra of synthesized compounds  were exhibited 3372.82cm-1 for associated NH of 
amines, 840-790cm-1 for Ar, CH=CH stretching, 1640-1620cm-1 and 1600-1400cm-1for 
C=O stretching. The 1H NMR spectra all the synthesized  compounds showed multiplets in 
the range δ 7.5-8.04 for the protons of aromatic ring In addition, 1H NMR spectra of these 
compounds signals arising from possible –CH2– structure at 3.3 ppm .The  Ar-NH– proton 
structure of synthesized  was also supported by 1H-NMR spectra. Mass spectrums of the 
synthesized compounds were in full agreement with their molecular weights and studies 
showed satisfactory results. 
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8.2 BIOLOGICAL STUDIES 
8.2.1ANTI- BACTERIAL ACTIVITY 
Disc Diffusion Method 
All the newly synthesized compounds were screened for their preliminary anti-bacterial 
activity against Six gram-positive bacteria strains, Micrococcus luteus NCIM 2169, 
staphylococcus aureus NCIM 2079, Bacillus subtilis NCIM 2063, Cornybacterium NCIM 
2640, Bacillus lintus NCIM 2018 and Staphylococcus albus NCIM 2178, and six gram-
negative bacteria strains, Escherichia Coli  NCIM 2065, Pseudomonas aruginosa 
NCIM 2018, Rhodosporum ruberum NCIM 5128, Vibrio cholera NCIM 1738, Salmonella 
Paratyphii NCIM 2075, Klbsellia pneumonia NCIM 2957 by disc diffusion method at a 
concentration of 100µg/disc. 
 
9 Among the synthesized compounds, compound B1P, B1PB, B1AZ, B1T and B1B at 
100µg/disc was found to be significant active against most of the screened bacteria 
when compared with standard drug (Ciprofloxacin 5µg/disc). 
S
N
N
H
N
N
N
O
H2N
HN OHBr
 
9 Among the synthesized compounds, Compound B1P, B1PB, and B1B at 100µg/disc 
demonstrated more zone of inhibition against Escherichia coli when compared with 
standard drug Ciprofloxacin (5µg/disc). 
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MIC STUDIES 
9 Based on the preliminary anti-bacterial activity screening result, active compounds 
were selected for determining minimum inhibitory concentration (MIC) by 2-fold 
serial dilution method.  
9 Among the screened compounds, compound B1P, B1PB, B1M, and B1B was found 
to possess anti-bacterial activity at 6.25µg/ml concentrations level for Staphylococcus 
aureus, Escherichia Coli. 
8.2.2 ANTI- FUNGAL ACTIVITY 
Disc Diffusion Method 
All the newly synthesized compounds were screened for their preliminary anti fungal 
activity against Six fungal strains, Candida albicans NCIM 3100, Monococcus purpureus 
MTCC 1090, Aspergillus niger MTCC 1344, Trichophyton rubrum MTCC 3272, 
Aspergillus fumigates MTCC 1811, Aspergillus parasites MTCC 2796 by disc diffusion 
method at a concentration of 100µg/disc. 
 
9 Among the synthesized compounds, compound B12N, B14N was found to be 
significant active against most of the screened fungi when compared with standard 
drug (Clotrimazole 5µg/disc). 
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9 Among the synthesized compounds, Compounds B1PB, B1Br, B12C, B1AZ, B12N, 
B14N and B1B demonstrated more zone of inhibition against aspergillus fumigates 
when compared with standard drug Clotrimazole (5µg/disc). 
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MIC STUDIES 
9 Based on the preliminary anti-fungal activity screening result, active compounds were 
selected for determining minimum inhibitory concentration (MIC) by 2-fold serial 
dilution method. 
9 Among the synthesized compounds, compound B14C was found to possess anti 
fungal activity at 6.25µg/ml concentration level for aspergillus niger. 
                
8.2.3 IN-VITRO ANTI-OXIDANT ACTIVITIES  
All newly synthesized compounds were screened for in-vitro anti-oxidant activity by 
DPPH, FRAP and ABTS assay method at the concentration of 25µg/ml, 50µg/ml, 75µg/ml 
and 100µg/ml.  DMSO used as a solvent, ascorbic acid used as an standard for DPPH and 
ABTS, ferrous sulphate is used as an standard for FRAP method.   
DPPH  
The result of in-vitro anti-oxidant activity by DPPH method shows that among the 
screened compounds, compound B12N, B14N, B1Br, B12C, B1PB, B14C and B1AP have 
significant anti-oxidant activity with EC50 value 22.45, 22.9, 23.58, 24.15, 25.12, 25.13 and 
31.75 respectively. The other synthesized compounds showed mild anti-oxidant activity.   
FRAP 
   Among the synthesised derivatives B1P, B1PB, B1M, and B1AZ are having the R2 
value near to the standard ferrous sulphate acid showed good anti-oxidant activity. 
ABTS 
The result of in-vitro anti oxidant activity by ABTS method shows that among the 
screened compounds, compound B12C, B14C, B1Br, B12N, B14N, B1P and B1AP have 
significant anti oxidant activity with EC50 value 22.05, 22.49, 22.83, 23.70, 24.30, 24.62 and 
30.97 respectively. The other synthesized compounds showed mild anti oxidant activity.  
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8.2.4 IN-VITRO CYTOTOXICITY ACTIVITY 
9   Six compounds were screened for in-vitro cytotoxicity testing and five compounds shown 
activity in the tested concentrations 0.1, 1.0, 10, 100µM and one compound doesn’t shown 
activity in tested concentrations 0.1, 1.0, 10, 100µM. 
 
II. CONCLUSION  
9 Twelve N-mannich bases of 5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydraziny 
lidene]-2,4-dihydro-3H-pyrazol-3-one (BTZP) were prepared. 
9 The structure of the compounds were characterized by UV, IR, NMR and Mass 
spectral data, and evaluated for their in-vitro anti-microbial, in-vitro anti-oxidant and in-
vitro cytotoxicity activity. 
9 The compounds containing substitution of electron donating groups present at phenyl 
ring (B1P, B1M, B1AZ, B1AP, B1T and B1B) imparted significant anti-bacterial activity  
against compared with electron withdrawing group attached compounds (B1Br, B12C, 
B14C, B12N, B14N). Particularly, the 2nd position of pyrazolone ring containing bulky 
group link through –CH2-NH- Bridge (B1AZ and B1B) showed anti-bacterial activity and 
anti-fungal against all tested strains at 100µg/disc level. The compounds containing 
electron withdrawing group (B1PB, B1Br, B12C, B12N and B14N) imparted moderate 
anti fungal activity, particularly aspergillus niger, aspergillus fumigates, and aspergillus 
parasites to the resulting N-mannich base containing pyrazolone derivatives. 
9 The DPPH and ABTS in-vitro anti-oxidant methods result of the synthesised 
compound review that the electron withdrawing groups attached at the para position of N-
methyl benzenamine ring compounds (B12N, B14N, B1Br, B12C, B1PB, B14C and 
B1AP) showed better anti -oxidant activity. 
9 All the  tested compounds showing the in-vitro cytotoxicity activity except B1B 
compound but  this compound  showing  moderate to significant anti microbial activity  
aganist  all the tested strains. So this compound may consider for further modification for 
its biological activity. 
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Table: 9.1 
LIST OF NEWLY SYNTHESIZED COMPOUNDS 
S.No Compound 
code 
Structure and IUPAC Name 
 
1 
 
 
B1P S
N
N
H
N
N
N
O
H2N
HN OHBr
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2-{[(4-hydroxyphenyl)amino]
methyl}-2,4-dihydro-3H-pyrazol-3-one  
 
2 
 
B1PB 
S
N
N
H
N
N
N
O
H2N
HNBr COOH
4-[({3-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-5-oxo-4,5-dihydro-1H-pyrazol-1-
yl}methyl)amino]benzoic acid
 
 
3 
 
B1M 
S
N
N
H
N
N
N
O
H2N
HNBr OCH3
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2-{[(4-methoxyphenyl)
amino]methyl}-2,4-dihydro-3H-pyrazol-3-one
 
4 
 
 
B1Br S
N
N
H
N
N
N
O
H2N
HNBr Br
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2-{[(4-bromophenyl)amino]
methyl}-2,4-dihydro-3H-pyrazol-3-one
 
5 
 
B12C 
      
S
N
N
H
N
N
N
O
H2N
HN
Br
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2-{[(2-chlorophenyl) 
amino]methyl}-2,4-dihydro-3H-pyrazol-3-one
Cl
 
 
6 
 
 
B14C S
N
N
H
N
N
N
O
H2N
HN
Br
Cl
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2-{[(4-chlorophenyl)amino]
methyl}-2,4-dihydro-3H-pyrazol-3-one
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7 
 
 
B1AZ 
4-[({3-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-5-oxo-4,5-dihydro-1H-pyrazol-1-
yl}methyl)amino]-2-phenyldiazene
S
N
N
H
N
N
N
O
H2N
HNBr N N
 
8 
 
 
B12N S
N
N
H
N
N
N
O
H2N
HNBr
O2N
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2-{[(2-nitrophenyl)amino]
methyl}-2,4-dihydro-3H-pyrazol-3-one
 
9 
 
B14N 
S
N
N
H
N
N
N
O
H2N
HNBr
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2-{[(4-nitrophenyl) 
amino]methyl}-2,4-dihydro-3H-pyrazol-3-one
NO2
 
 
10 
 
 
B1AP S
N
N
H
N
N
N
O
H2N
HN
N
Br
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2-[(pyridin-2-ylamino)
methyl]-2,4-dihydro-3H-pyrazol-3-one  
 
11 
 
 
B1T S
N
N
H
N
N
N
O
H2N
HN
Br
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2-{[(2-methylphenyl)amino]
methyl}-2,4-dihydro-3H-pyrazol-3-one
 
12 
 
 
B1B S
N
N
H
N
N
N
O
H2N
Br HN
N
S Br
5-amino-2-{[(6-bromo-1,3-benzothiazol-2-yl)amino]methyl}-4-[2-(6-bromo-1,3-benzothiazol-2-yl)
hydrazinylidene]-2,4-dihydro-3H-pyrazol-3-one
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1.1 BENZOTHIAZOLE1-31  
Benzothiazole is a heterocyclic compound, weak base, having varied biological activities 
and still of great scientific interest now a days. Being a heterocyclic compound, benzothiazole 
finds use in research as a starting material for the synthesis of larger, usually bioactive structures. 
Its aromaticity makes it relatively stable, although as a heterocyclic, it has reactive sites, which 
allow for functionalization. Benzothizole is a colorless, slightly viscous liquid with a melting 
point of 2˚C, and a boiling point of 227-229˚C, the density of benzothiazole is 1.644gm/ml, and 
molecular mass is 139.19g/mol. Benzothiazole has no household use. It is used in industry and 
research. 
 A large number of therapeutic agents are synthesized with the help of benzothiazole 
nucleus. During recent years there have been some interesting developments in the biological 
activities of benzothiazole derivatives. These compounds have special significance in the field of 
medicinal chemistry due to their remarkable pharmacological potentialities1. 
Despite numerous attempts to develop new structural prototype in the search for more 
effective antimicrobials, benzothiazole still remain as one of the most versatile class of 
compounds against microbes2 and therefore, are useful substructures for further molecular 
exploration. Benzothiazole derivatives have attracted continuing interest because of their varied 
biological activities viz. antitumor3, antitubercular4, immunosuppressive activities5, 
anticonvulsant6, anti-inflammatory7, antidiabetic8. Substituted 2-arylbenzothiazoles have 
emerged in recent years as an important pharmacophores in non-invasive diagnosis of 
Alzheimer’s disease. Recently benzothiazole derivatives have been evaluated as potential 
amyloid-binding diagnostic agents in neurodegenerative disease and as selective fatty acid amide 
hydrolase inhibitors9. Azomethine linkage has also shown an array of biological activities viz. 
antimicrobial10.   
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SYNTHESIS 
Many methods had been reported in literature. Some methods were listed in this study. 
1) Scheme-1: Solvent free synthesis 
Synthesis of 2-substituted benzothiazoles by condensation of 2-aminothiophenol with 
various saturated and olefinic fatty acids under microwave in solvent free condition (path-A) 
with the use of catalyst P4S10 in (path-B), the reaction was successful in terms of yield and was 
completed within 3-4 min11. 
R
OH
O SH
NH2
N
S
R
MW MW
P4S10
Solvent free
Solvent free
 
2) Scheme-2: Synthesis of cynosubstituted conjugated benzothiazoles  
They explored synthesis of benzothiazole based organic nano-particles. The elaboration 
of conjugated system was performed by reacting equimolar quantities of 4 and 5 in dry THF and 
terbutyl alcohol at 50ºC while a small amount of terbutylammonium hydroxide was slowly 
dropped in mixture12. 
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SH S
NH3C
S
N
CN
S
N
H
O
S
N
CN
N
S
1 2 3
4
5
6  
 
INTRODUCTION 
 
DEPT.OF PHARMACEUTICAL CHEMISTRY   3 
3) Scheme-3: Suzuki-Miyaura coupling reaction 
Development of microwave promoted Suzuki-Miyaura reaction 2-chlorobenzothiazole 
with phenyl boronic acid was carried out using Pb(PPh3)4as a catalyst. This reaction provides the 
adduct 6a with excellent regioselectivity. The bis adduct 2,6-diphenyl benzothiazole(7) by the 
catalysis of 2,6-dichloro benzothiazole with excess of phenyl boronic acid13. 
           
N
S
Cl
Cl
N
S
PhB(OH)2
Pd(PPh3)4
Ligand Na2CO3
dioxane/H2O
N
S
Cl
6 a
7
 
 
4) Scheme-4: Solid phase synthesis- 
Conversion of resin bound isothiocynate 3 was to N-acyl, N-phenyl thioureas in general 
structure 4, X=H of 4 is cyclized to 2-acyl aminobenzothiazole 5 by treatment with 6 equivalent 
of bromine in acetic acid. Finally the desired compound 6 were obtained by treatment of 5 with 
4% hydrazine monohydrate in ethanol14.  
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5) Scheme-5 
Development of simple procedure to prepare a series of pyrimido[2,1-b]benzothiazoles 
by the conjugation addition of the imino nitrogen of 2-aminobenzothiazoles to alkyne β- carbon 
atom of acetylinic acid followed by ring closure15. 
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6) Scheme-6 
Synthesis of substituted 2-mercaptobenzothiazoles by varying substituent’s at 4, 5, and 6-
position in the benzothiazole ring system. The synthesis of final compounds involves two steps- 
1) Substituted anilines were converted to its hydrochloride salts. 2) This aniline hydrochloride 
salt was then cyclized to substituted 2-mercaptobenzothiazoles by reacting with carbon 
disulphide in presence of sulfur in an alkaline medium16. 
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7) Scheme-7 
Synthesis of new 2-substitued benzothiazole derivatives by refluxing benzothiazolyl 
carboxyhydried with different aryl acids in phosphoryl chloride17. 
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8) Scheme-8 
Synthesis of 2-aryl substituted benzothiazole derivatives by refluxing o-aminothiophenols 
with substituted benzoic acids in presence of polyphosphoric acid at 220°C18.  
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BIOLOGICAL ACTIVITY 
1) Anti-microbial activity 
Microbes are causative agents for various types of disease like pneumonia, ameobiasis, 
typhoid, malaria, common cough and cold various infections and some severe diseases like 
tuberculosis, influenza, syphilis, and AIDS as well. Various approaches were made to check the 
role of benzothiazole moiety as antimicrobial agent from the discovery of molecule to the present 
scenario. 
synthesis of series of pyrimido [2,1-b] benzothiazoles by conjugation addition to imino 
nitrogen of 2-aminobenzothiazoles to alkyne β-carbon atom of acytylenic acid followed by ring 
closure and synthesized compounds are studied for antimicrobial activity against E.coli and 
Enterobacter as test organisms at conc 100μg per disc using vancomycine and meropenam as 
standard drug19.  Synthesis of new benzothiozole and benzisoxazole from 2-amino 5/6-
hydroxybenzothiazole, 6-hydroxy-3-methyl-1, 2-benzisoxal and different dihaloalkanes and 
screened for their antimicrobial activity against Staphylococcus aureus, and E. coli by disc 
diffusion method and anti fungal activity against Aspergillus flavus, and Candida albicans. 
Ciprofloxacin (10μg/ml) and fluconazole (10μg/ml) were used as standard drug for antibacterial 
and antifungal activity respectively20.some new 2-mercapto- benzothiazoles and coreleted the 
effect on antimicrobial potency by varying the substituents in benzene part of the benzothiazole 
ring system. Anti-microbial screening was performed against E. coli, S. aureus, C.albicans and 
antifungal activity against Aspergillus flavus and Candida albicans at conc. 100μg/ml using agar 
plate Kirby-Bauer disc diffusion method in DMF as solvent. Ofloxacine (100μg/ml) and 
griciofulvin (100μg/ml) were used as standard drug for antibacterial and antifungal activity 
respectively21. synthesis of some new 2-substituted benzothiazole derivatives by refluxing 
benzothiazolylcarboxyhydrazide with different aryl acids in phosphoryl chloride and screened 
the derivative for antimicrobial activity against B. subtilis, E. coli and P.aeruginosa by disc 
diffusion method at conc. 100μg/ml. The activity was compared to antibiotic ciprofloxine22. 
Synthesis of series of benzothiazole-2-yl-dithiocarbamates along with copper complexes via 
reaction of suitable alkyl or heteroaryl halide with sodium salt of benzothiazole-2-yl-
dithiocarbamic acid followed by complexation with copper sulphate and selected derivatives 
checked for their schistosomicidal activity againstSchistosoma mansoni23. 
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S
N
O N
N
Br
2-((5-(2-bromobenzyl)-1,3,4-oxadiazol-2-yl)methyl)benzo[d]thiazole  
2) Anti-cancer activity 
       Refluxing of o-aminophenols with substituted benzoic acid in presence of polyphosphoric 
acid at higher temperature to get aryl substituted benzothiazoles and evaluated them against 
Human Cervical Cancer cell lines as anticancer drugs24. Synthesis of  benzothiazole containing 
phthalimide and studied their anti-cancer activity on human carcinoma cell lines25. Synthesis 
carbon 11 labeled fluorinated 2-aryl benzothiazoles used for protein emission tomography (PET) 
to image tyrocinekinese in cancer26. Synthesis of benzothiazole derivatives and evaluated for in 
vitro cytotoxic activity against HL-60 and U-937 cell lines using 5-flurouracil, and cisplatin as 
std. drug. In silico pharmacokinetic study revealed that benzothiazole dimere were free from 
teratoginicity, irritation and sensitivity properties than monomers. The QSAR study showed that 
increase in hydrogen donor count is conductive for cytotoxic activity of benzothiazole 
derivatives against HL-60 cell lines27. Synthesis of fluorinated analogues of 2-(4-aminophenyl) 
benzothiazoles which successfully block C-oxidation. Fluorinated benzothiazole analogue 2-(4-
amino-3-methylphenyl)-5-fluorobenzothiazole (5F203, NSC 703786) (1d), exhibit selective and 
potent anticancer activity. It is the favored analogue for clinical consideration possessing 
enhanced efficacy in vitro and superior potencies against human breast and ovarian tumor 
xenografts implanted in nude mice Its lysylamide prodrug, (Phortress, NSC710305), (1e) is 
under phase I clinical trials at the United Kingdom28. 
            
S
N
NH
H
N
N
S
N-((4-(benzo[d]thiazol-2-yl)phenylamino)methyl)-4-(benzo[d]thiazol-2-yl)benzenamine  
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3) Anthelmentic activity 
Synthesis of flurobenzothiazole comprising  sulfonamide pyrazole derivitives. They screened 
synthesized for anthelmentic activity by using earthworms (Peritumaposthum). Albendazole was 
used as standard drug. The compounds were evaluated by time taken for complete paralysis and 
death of worms29 
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N S N
N
C6H5HN CONH2
H
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O
. 
4) Anti-diabetic activity 
Synthesis of 2-amino[5`(4-sulphonylbenzylidine)-2,4-thiazolidnedione]-7-chloro-6-
flurobenzothiazole series and screened for their antidiabetic activity on albino rat by alloxan 
induced tail tipping method30. 
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5) Cyclooxygenase inhibitor activity 
Pyrazolones and pyrazolinones rank among the more venerable non‐steroidal anti-
inflammatory agents. Phenylbutazone and its congeners incorporating a pyrazoline‐3, 5‐dione 
structure are more potent anti-inflammatory agents. In the recent years a number of Benzo- 
thiazole derivatives have been synthesized and found to display anti-inflammatory activity. 
Synthesis of series of 2-[(2-alkoxy-6-pentadecylphenyl) methyl] thio-1-Hbenzimidazoles/ 
benzothiazole from anacardic acid (pentadecyl salicylic acid) and investigated their ability to 
inhibit human cyclooxygenase enzyme-231. 
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1.2 PYRAZOLONES32-40 
Pyrazolone moiety (a five-membered lactam ring containing two nitrogens and ketone in the 
same molecule or alternatively a derivative of pyrazole possessing an additional 
carbonyl/hydroxy group) has gaining the focus of medicinal chemists for over last 100 years 
because of the outstanding pharmacological properties shown by several of its derivatives. Due 
to use of such ring system as the core structure in many drug substances, covered wide range of 
pharmacological applications. Soon after the discovery of phenyl hydrazine A by Emil Fischer 
in 1883, Ludwig Knorr (Fischer’s assistant) attempted to synthesize a quinoline derivative. The 
product however, isolated after methylation was found to be a pyrazolone derivative and was 
named as antipyrine or phenazone B Because of its promising antipyretic and analgesic 
activities antipyrine was launched by Hoechst Pharmaceuticals. For the next 20 years, 
antipyrine became the most widely used drug in the world, proving highly successful for 
treating fever and flu like infections, until acetylsalicylic acid (aspirin) began to outsell it32. 
HN
NH2
A
N
N
O
B  
Since the introduction of antipyrine, the first pyrazolone derivative used in the management 
of pain, inflammation and fever into clinical use in 1884, great attention has been focused on 
pyrazole derivatives as potent anti-inflammatory, analgesic and antipyretic agents. As a result, a 
large number of pyrazoles have been obtained and some have gained application on the clinical 
level. 
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Interest in this field has been intensified after the discovery of the natural pyrazole C-
glycoside pyrazofurin 4-hydroxy-3-β-D-ribofuranosyl-1H-pyrazole-5-carboxamide.This 
antibiotic was reported to possess a broad spectrum of antimicrobial and antiviral activities in 
addition to being active against several tumor cell lines33.  
 
Pyrazolone, as a prominent structural motif, is found in numerous pharmaceutically active 
compounds. Due to the easy preparation and rich biological activity, pyrazolone framework 
plays an essential role and represents an interesting template for combinatorial and medicinal 
chemistry with having a wide range of bioactivities such as antimicrobial34, anticancer35, anti-
inflammatory36, analgesic36, anti-pyretic36, anti-bacterial37, anti tubercular38 activities. It has 
been found that these compounds have hypoglycemic activity, and are also known as inhibitors 
and deactivators of liver alcohol dehydrogenase and oxidoreductases. It has been shown in vivo 
that some of the pyrazole derivatives have appreciable antihypertensive activity. These 
compounds also exhibit properties such as cannabinoid hCB1 and hCB2 receptor, inhibitors of 
p38 Kinase, CB1 receptor antagonists. 
Pyrazolin-5-one derivative, 3-methyl-1-phenyl-2-pyrazolin-5-one has been reported to be a 
promising candidate for the treatment of neonatal hypoxic-ischemic encephalopathy and 
paraquat poisoning due to its free radical scavenging activity.  
Recently an important natural mediator of inflammation Leucettamine B was isolated and 
since then attempts to synthesis this compound and its analogues were continued. 
O
O
N
N
CH3
CH3
O
Leucettamine B
 
A new pyrazolone compound III, Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one, also 
known as MCI-186), has been developed as a promising drug for brain ischemia and has also 
been reported to be effective for myocardial ischemia. More recently, a series of pyrazolone 
derivatives have been synthesized as potent inhibitors of protease-resistant prion protein 
accumulation for the treatment of fatal neurodegenerative diseases.  
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Pyrazolo[3,4-d]pyrimidine derivatives have been found to possess antitumor and 
antileukemia activity and pyrazolo [4,3-e]-1,2,4-triazolo[1,5-c] pyrimidine derivatives have 
been found to be highly potent and selective human A3, A2 and A2B adenosine receptor 
antagonists. Among the already marketed COX-2 inhibitors that comprise the pyrazole nucleus, 
celecoxib; 4-[5-(4-methylphenyl)-3-(trifluorophenyl)-1H-pyrazol-1-yl] benzene sulfonamide 
proved to be potent and GI safe anti-inflammatory and analgesic agent.  
A number of methods have been developed for the preparation of pyrazolone derivatives. 
These methods are diverse, but frequently involve the condensation of a β-keto ester or β-keto 
aldehyde with substituted or unsubstituted hydrazines. These methodologies, although utilized 
for the preparation of a variety of pyrazolones, often require the use of refluxing conditions and 
lengthy reaction time, ideally 3-10 hrs. 
 
CHEMISTRY OF PYRAZOLONE39 
REACTIONS WITH ELECTROPHILIC REAGENTS 
Oxidation at nitrogen 
The preparation of 1-hydroxypyrazoles can employ per acidic conditions or basic 
conditions. When it is the pyrazolyl anion it reacts with the oxidising agent, dibenzoyl peroxide. 
Alkylation at nitrogen 
3(5)-Substituted pyrazoles which have an N-hydrogen, can in principle give rise to two 
isomeric N-alkyl pyrazoles, after loss of proton from nitrogen and there is further reaction 
producing an N, N1-disubstituted quaternary salt. 
Acylation at nitrogen 
The introduction of an acyl or phenylsulfonyl group onto a pyrazole nitrogen is usually 
achieved in the presence of a weak base such as pyridine; such process proceed via imine 
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nitrogen acylation, the N+-H-deprotonation. Since acylation, unlike alkylation, is reversible, the 
more stable product is obtained. 
N
N
H
N
N
AcCl
phH, rt
80%
N
N
H
t-Bu
NH
N
t-Bu
AcCl
pyridine,rt
79%
N
N
t-Bu
AcAc  
The reactivity of the 3- and 5-azolones centres mainly on their ability to react with 
electrophiles such as halogens or to nitrate or undergo Vilsmeier formylation, the example is the 
formylation of antipyrine once used as an analgesic. Many dyestuffs have been synthesized via 
coupling of aryldiazonium cations with 5-pyrazolones at C-4 tartazine is such an example. 
N
N
Me
O
Ph
N
N
Me
O
Ph
MeI
MeOH,100oC
Me
DMF, POCl3
65OC aq.NaHCO3
N
N
Me
O
Ph
Me
OHC
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Pyrazole reacts with cyanamide very efficiently to produce an N-derivative which can be 
utilized by reaction with primary or secondary amines to synthesise guanidines.  
N
N
H
N
N
H2N N
+H2 .Cl-
NH2CN,HCl
dioxane, reflux
95%
 
Pyrazolones also condense with aldehydes in aldol-type processes, or react with other 
electrophiles such as carbon disulphide, in each case reaction presumably proceeding via the 
enol tautomer, or its anion. In basic solution oxazol-3-ones alkylate either or nitrogen. 
N
N
Me
O
Ph
KOH, CS2
then nBuBr
70% N
N
Me
HO
Ph
n-BuS
S
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Aminopyraole undergoes substituent-N-acetylation and easy electrophilic bromination at C-
4. Diazotization and a subsequent Sandmeyer reaction provides route to azidopyrazoles. 
N
N
Me
O
Ph
N
N
Me
O
Ph
BrNBS, AlBN
CHCl3, refux
73%
Pb(OAc), BF3.Et2O
MeOH, 0OC
59%
Br
MeO2C
C CH2
 
 
    Diazotisation of 4-aminopyrazoles, then deprotonation yields stable diazopyrazoles. 
 
N
N
H
MeH2N
Me N
N
H
Me+N2
Me N
N
Me
Me
N2
NaNO2
aq.HCl, 50C 2N NaOH
85%
3,5-dimethyl-1H-pyrazol-4-amine  
 
SYNTHESIS40 
Many methods are available for synthesizing pyrazoline derivatives. Most of the methods 
make use of and α, ß-unsaturated carbonyl compounds. 2-pyrazolines were synthesized by 
reacting α, ß-unsaturated aldehydes or ketones with aryl hydrazine. 
Different solvents and widely different experimental conditions were employed to get the 
product. Included in these were the reactants being refluxed in ethanol maintaining reaction 
time varying from 10 min to 3 hrs. 
Eg: -acrylaldehyde and hydrazine gives 1,2- pyrazolines. 
HC
CH2
CHO
H2N NH2
CH2
HC CH2
NH
H2N
N
H
N
 
Pyrazolines may be oxidized to pyrazoles by bromine or mercuric oxide. If either carbon 
atom of the double bond is attached to a halogen atom, then a pyrazole is obtained. 
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1-Phenyl, 2-pyrazolines was synthesized from the reaction between acrolein and phenyl 
hydrazine. 
H2C CHCHOH
HN NH2
H2C CH
C
H
N
H
N
N
N
 
 
The phenyl hydrazide that was initially formed was then cyclized under specific reaction 
conditions to yield the product. 
From 1,3-dicarbonyl compounds and hydrazines or hydroxylamine: 
Pyrazoles can be made from a 1,3-dicarbonyl component and a hydrazine or hydroxylamine 
respectively.  
N
N
O
O
H
NH2
HN
-2H2O
3-methylpentane-2,4-dione
 
1.3 MANNICH BASES41-43 
In 1912 Mannich and Krosche discovered the property of formaldehyde to bind an amine 
with a carbon acid via a methylene bridge (Mannich, Kather, 1919). This method was utilized 
to obtain pharmaceutical products by implication of acid components, which were recognized 
like substances with therapeutic action41. 
The Mannich reaction consists on the condensation of a CH-activated compound with a 
primary or a secondary amine and a non-enolizable aldehyde or ketone to afford β-amino 
carbonyl derivatives known as Mannich bases42. 
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Ketonic amines prepared from the condensation of a ketone or a primary or secondary 
amine. The product formed is referred to as a Mannich base which can act as the equivalent of 
an alpha, beta unsaturated ketone in synthesis. The so called mannich reaction refers to a family 
of transformations that involve three fundamental reagents: a primary or secondary amine, an 
aldehyde, and an active methylene compound. These reagents condense, with the release of 
water, to form a Mannich base.  
The Mannich reaction is an example of nucleophilic addition of an amine to a carbonyl 
group followed by elimination of a hydroxyl anion to the Mannich base. The Mannich base is 
an electrophile which reacts in step two in a second nucleophilic addition with a carbanion 
generated from a compound containing an acidic proton. The Mannich reaction is also 
considered a condensation reaction42. 
REACTION MECHANISM 
The Mannich Reaction has a two part reaction mechanism:- 
1. Formation of the mannich base electrophile in a nucleophilic addition. 
2. Amino alkylation of an acidic hydrogen containing compound. 
 
 
In the second step of the reaction a carbanion is generated from a CH acidic compound 
under the influence of a base which then attacks the iminium salt in a second nucleophilic 
addition. 
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Modern theoretical consideration permits inclusion of acid -NH, -OH or –SH containing 
compounds as qualified active hydrogen compounds susceptible to the mannich amino 
methylation process. 
H C
O
H CH3COR' H2N
H2
C
H2
C COR'NH4+Cl-
 
If it is the primary or secondary amine then it may combine with one or two additional 
molecules of the aldehyde and active compound. 
 
If the active hydrogen compound has two or three active hydrogen’s the mannich base may 
condense with one or two additional molecules of aldehyde and ammonia or amine43. 
 
Example:  
 
 
1.4 ANTIMICROBIAL AGENTS44 
An anti-microbial is a substance that kills or inhibits the growth of microorganisms such 
as bacteria, fungi, or protozoans. Antimicrobial drugs either kill microbes (microbiocidal) or 
prevent the growth of microbes (microbiostatic). Disinfectants are antimicrobial substances 
used on non-living objects or outside the body. 
1.4.1ANTIBACTERIAL AGENTS 
The synthetic or naturally occurring agents, which can kill or inhibit the growth of bacterial 
cells, are called antibacterial agents. 
The year 1935 was important in chemotherapy of systemic bacterial infections. The 
discovery of antimicrobial activity of penicillin turned the attention of investigators to 
antibiotics as potentially useful chemotherapeutic compounds. In 1940’s and 1950’s 
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streptomycin, tetracyclines, chloramphenicol, polymyxin and Bacitracin greatly increased the 
range of effectiveness of antibacterial chemotherapy. 
 
 
Mechanism of action 
The goal is to limit toxicity to the host and maximize chemotherapeutic activity affecting 
invading microbes only. The mechanisms of action of antibacterial agents are 
1. Inhibition of cell wall synthesis 
Inhibition of cell wall synthesis leads to bacterial cell lysis and death. Since animal cells do 
not have a cell wall, they are unaffected by such agents. E.g. Penicillins and cephalosporins. 
 
Methicillin sodium 
2. Inhibition of protein synthesis 
Most of the antibacterial agents that inhibit protein synthesis interact with the bacterial 
ribosome. The difference between composition of bacterial and mammalian ribosomes gives the 
compounds their selectivity. 
E.g. Netimicin, Amikacin. 
 
Chloramphenicol 
3. Inhibition of bacterial metabolism 
The antimetabolites are synthetic compounds that interfere with bacterial synthesis of folic 
acid. Inhibition of folate synthesis leads to cessation of cell growth and some case, to bacterial 
cell death. The principal antibacterial antimetabolites are sulphonamides and trimethoprim. 
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4. Inhibition of nucleic acid synthesis 
Inhibition of nucleic acid function prevents cell division and the synthesis of essential 
enzymes. Agents acting in this way include Nalidixic acid and Proflavin. 
 
Nalidixic acid 
 
5. Alteration of cell wall membrane permeability 
Some antibacterial agents behave as cationic, surface active compounds that disrupt the 
permeability of both the outer and cytoplasmic membranes of gram negative bacteria. E.g. 
peptide antibiotics, polymyxin-B, Amphotericin-B. 
 
DRUGS USED IN THE TREATMENT 
1. Sulphonamides and related drugs 
Sulphonamides were the first anti-microbial agents (AMAs) effective against pyrogenic 
bacterial infections. A free amino group in para position is required for antibacterial activity. 
They act as antimetabolites. 
 
Sulphamethoxazole 
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2. β-Lactum antibiotics 
These are antibiotics having a β- lactum ring. The two major groups are Penicillins and 
Cephalosporins. Monobactams and carbapenems are the newer additions. 
 
Penicillins  
3. Tetracyclines 
These are a class of antibiotics having a nucleus of four cyclic rings. All are obtained from 
soil actinomycetes. 
 
 
4. Quinolones and Fluoroquinolones 
These are entirely synthetic antimicrobials having a quinolone structure that are active 
against gram negative and gram positive bacteria. 
Ciprofloxacin  
5. Miscellaneous 
This includes aminoglycosides (E.g. streptomycin) and macrolide antibiotics (E.g. 
Erytromycin). 
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Erythromycin 
 
1.4.2 ANTIFUNGAL AGENTS 
Classification 
ACCORDING TO CHEMICAL STRUCTURE: 
1) Antifungal antibiotics:- 
a) Polyenes: Amphotericin B, Nystatin, Natamycin 
b) Heterocyclic Benzofurans: Griseofulvin 
2) Synthetic Antifungal drugs:- 
i) Azoles: 
(a) Imidozole derivatives: Clotrimazole, Econazole, Miconazole, 
       Ketoconazole, Oxiconazole 
(b) Triazole derivatives: Fluconazole, Intraconazole 
ii) Allylamines: Terbinafine, Naftifine 
iii) Thiocarbamate;Tolnaftate 
iv) Derivatives of Unecyclenic acid: Ointment”Zincudin” & Undecin 
v) Pyrimidine Antagonists: Flucytosine 
vi) Echinocandin: Caspofungin, Micafungin, Anidulafungin 
vii) Antifungal drugs with other chemical structure: 
(a) Degudinium chloride 
(b) Iodine Drugs: KI 
(c) Drugs of salicyclic acid 
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ACCORDING TO MODE OF ACTION: 
1) Alter cell permeability: Azoles, Polyenes, Terbinafine 
2) Disrupt microtubule function: Griseofulvin 
3) Ergosterol binding: Amphotericin 
4) DNA-RNA inhibitors: Flucytosine 
5) Ergosterol synthesis inhibitors/P450 inhibitors: Ketoconazole, Itraconazole, 
         Fluconazole, Voriconazole 
6) B(1-3) glucan inhibitors: Caspofungin, Micafungin, Anidulafungin. 
ACCORDING TO SITE OF ACTION: 
1) Systemic Antifungal Drugs 
i) For Systemic Mycoses: Amphotericin B, Flucytosine, Azoles, Echinocandins 
ii) For Mucocutaneous Mycoses: Griseofulvin, Terbinafine 
2) Topical Antifungal Drugs: Nystatin, Topical Azoles, Topical Allylamine 
1.5  CANCER:  
The term carcinoma is the medical term for a malignant tumor derived from epithelial 
cells. It was Celsius who translated carcino into the Latin cancer, also meaning crab. Galen 
used "oncos" to describe all tumors, the root for the modern word oncology. 
 
Hippocrates described several kinds of cancers. He called benign tumors “oncos”, 
Greek for swelling and malignant tumors “carcinos”, Greek for crab or crayfish. This name 
comes from the appearance of the cut surface of a solid malignant tumor; with a roundish hard 
centre surrounded by a pointy projection, vaugly resembling the shape of crab. He later added 
the suffix -oma, Greek for swelling, giving the name Carcinoma. 
 
 Since it was against Greek tradition to open the body, Hippocrates only described and 
made drawings of outwardly visible tumors on the skin, nose, and breasts. Treatment was based 
on the humor theory of four bodily fluids (black and yellow bile, blood, and phlegm). 
According to the patient's humor, treatment consisted of diet, blood-letting, and/or laxatives. 
Through the centuries it was discovered that cancer could occur anywhere in the body, but 
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humor-theory based treatment remained popular until the 19th century with the discovery of 
cells. 
Cancer is the gross distortion of the cell behavior caused by numerous gene mutations 
and numerous abnormalities in the production of functioning proteins. The specific 
abnormalities vary greatly, depending on the type of cancer as well as the type of tissue from 
which cancer has originated.  
Thus, there is not a single description of cancer or oncogenesis, because cancer is not a 
single disease. It is really a class of diseases all pertaining to unlimited cell growth that is 
potentially fatal to the organism.  
 
Cancer initiates from a single cell that has been transformed due to particular changes 
in its DNA. Some events such as exposure to radiation or exposure to chemical carcinogen, 
creates a change in genome. This may be a DNA mutation, or epigenetic modification. In 
comparison with normal cell, a neoplastic cell is hyper responsive to growth factors, under 
responsive to growth inhibitors, and has an increase in metabolic transport capabilities.  
 
Broadly, carcinomas are the cancers of epithelial cells; sarcomas are cancers of 
connective tissue or muscle cells, and leukemias are cancers of the blood or lymph systems.  In 
the normal human population, over 90% of all human cancers are carcinomas.  
 
Types of Tumors 
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¾ Different types of cancers  
Uterus                                                         Kidney  
Bladder                                                         Esophagus 
Melanoma                                                    Leukemia 
Ovary                                                            Non-Hodgkin lymphoma                                            
Brain and CNS                                            Multiple myeloma 
Breast                                                        Pancreas 
Colorectal                                                   Prostate  
Cervix                                                        Stomach    
Melanoma  
 Causes of Cancer  
Cancer is a diverse class of diseases which differ widely in their causes and biology. The 
common thread in all known cancers is the acquisition of abnormalities in the genetic material of 
the cancer cell and its progeny. Research into the pathogenesis of cancer can be divided into 
three broad areas of focus. The first area of research focuses on the agents and events which 
cause or facilitate genetic changes in cells destined to become cancer. Second, it is important to 
uncover the precise nature of the genetic damage, and the genes which are affected by it. The 
third focus is on the consequences of those genetic changes on the biology of the cell, both in 
generating the defining properties of a cancer cell, and in facilitating additional genetic events, 
leading to further progression of the cancer. Chemical carcinogens, Ionizing radiation, Hormonal 
imbalances, Immune system dysfunction, Heredity (45) and others. 
New Research in Cancer Treatment  
¾ Genetically engineered bacteria and viruses  
¾ Anti-cancer vaccines  
¾ Cancer markers  
¾ Cancer growth retarders / inhibitors 
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2.1 BENZOTHIAZOLE 
Anti-cancer activity 
 1. Malcolm F.G. Stevens et al (2001)46, has been reported a series of sulfamate salt 
derivatives of the potent and selective 2-(4-aminophenyl) benzothiazole antitumor agents has 
been prepared and their evaluation as potential prodrugs for parenteral administration carried out. 
The  sodium salts of [4-(1,3-benzothiazol-2-yl)phenyl] sulfamic acid (fig1) was found to be 
markedly less active than their parent amines against sensitive human tumour cell lines in 
vitro(MTT assay) at IC50 in the range <0.0001–0.001 Mm.  
                                                  S
N
NHSO3Na
  Fig 1 
2.Albert sun chi chan et al (2008)47, has been reported the ‘one pot’ condensation 
reaction for the synthesis of phthalic imide derivative (fig 2 benzothiazole containing 
phthalimide), exhibiting in vitro cytotoxic potential on human cancer cell lines in One Step ATP 
lite assay at 25 µg/mL concentration. 
                                                     
N
O
O
S
N
OCF3   Fig 2 
3. Yuichi sugano et al (2005)48, has been reported synthesized as a biologically stable 
derivative containing no nitro group. The highly potent derivative (fig 3) exhibited excellent in 
vivo inhibitory effect on tumor growth at 13ng/mL concentration. 
                                                
N
H
S
N
H
N R
Cl
Cl
O
O
R=Cyclopropyl Fig 3 
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4. Hoyun lee et al (2009)49, has been reported, to design and synthesis isatin-
benzothiazole analogs to examine their anti-breast cancer activity. Compounds examined were 
quite effective on all the cancer cell lines examined the compounds 4-chloro-1-
dimethylaminomethyl-3-(6-methyl-benzothiazol-2-ylimino)-1, 3-dihydroindol-2one (fig4) 
emerged as the most active compounds of this series. 
    
N
N
S
N
R
N
CH3
O
R1
R2
R1=H, R2,R3=Morpholinyl Fig 4 
5.Roman lesyk et al (2010)50 has been reported reactions of (benzothiazole-2yl)hydra 
zine with trithiocarbonyl diglycolic acid or 6-methyl-2-aminobenzothiazole with 2-carbethoxy 
methylthio-4-one have yielded starting 3- or 2-substituted 4-thiazolidiones which have been sub 
sequently utilized  in a knoevenagel condensation  for obtaining a series of 5-arylidene derivative 
es.in vitro anticancer activity of the synthesized compounds (fig5) and (fig6) were tested the anti 
cancer activity on leukemia, melanomia,lung, colon, renal, and prostate and breast cancers cell 
lines.  
S
N
H
N
S
N
Ar
O
S
Ar=2-(4-OMe-C6H4NHCOCH2O)-5Cl-C6H3,
S
NH
S
N
Ar
O
N
Ar=2-(4-OMe-C6H4NHCOCH2O)-5Cl-C6H3,
CH3
 
                                        Fig 5                                                Fig 6 
Anti-microbial activity 
6. Samir bondock et al (2009)51 has been reported synthesis of polyfunctionally 
substituted heterocyclic incorporating benzothiazole moiety via its reactions with some N-
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nucleophiles. Representative compounds (fig7) of the synthesized products were tested and 
evaluated as antimicrobial agents. 
                                   
S
N
N
H
N
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O
RR=H, Ph  Fig 7 
7. Samir bondock et al (2010)52 has been reported in an attempt to find a new class of  
antimicrobial agents, a series of thiazole, thiophene, pyrazole and other related products 
containing benzothiazole moiety were prepared. These compounds (fig8) were screened for their 
antibacterial activity and antifungal. 
                             
S
N
HNPh N
N
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O
Ar  Fig 8 
8. Balram soni et al (2010)53 has been reported as benzothiazole has proven to be good 
antimicrobial agent, a novel series of schiff bases of benzothiazole derivatives were synthesized. 
All the synthesized compounds (fig9) were screened for their antimicrobial activity. 
                  
S
N
NHCH2CH2
NN
N C
H
SH
R
R=H, 4-OH, 2-NO2, 3-NO2, 2-Cl,4-N(CH3)2, 4-OCH3 Fig 9 
9. Barot Hitesh k et al (2010)54 has been reported synthesized 2-amino-7-chloro-6-
fluoro benzothiazole by using 4-fluoro-3-chloroaniline and potassium thiocyanate. The title 
compound was screened for anti-bacterial (agar diffusion method) and anti oxidant activity 
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(ferric ion reduction method) and inhibition of denaturation of protein. Most of the compounds 
(fig10) have shown promising activity. 
                               
S
N
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H
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OCH3
OCH3
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Fig 10 
10. Sohail saeed et al (2010)55 has been reported five series of thiourea derivatives 
bearing benzothiazole moiety (20 compounds) were efficiently synthesized and evaluated for 
antimicrobial and anticancer activities. In preliminary MTT cytotoxicity studies, the thiourea 
derivatives (fig11) were found most potent. 
                                       
R1 NH
N
H
S
NO S
R
R=H, NO2, NH2, Br
R1=4-Nitrophenyl, 2-thiophene, n-butyl Fig 11 
Anti-inflammatory activity 
11. Paramashivappa et al (2003)56, has been reported a series of 2-[(2-alkoxy-6-
pentadecyl phenyl) methyl] thio-1-Hbenzimidazoles/ benzothiazole from anacardic acid 
(pentadecyl salicylic acid) and investigated their ability to inhibit human cyclooxygenase 
enzyme-2. The active compounds were screened for cyclooxygenase-1 (COX-1) inhibition. 
Compound 2-(2-methoxy-6-pentadecylbenzylthio)benzo[d]thiazole (fig 12) is more than 470-
fold selective towards COX-2 compared to COX-1. 
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Fig 12 
12. Young-Rae et al (2011) 57, has been reported the effects of a benzothiazole analog, 
SPA0537 (fig 13) exerts anti-inflammatory effects in rheumatoid FLS through the inhibition of 
the NF-jB pathway. Therefore, it may have therapeutic value for the treatment of rheumatoid 
arthritis. 
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Fig 13 
13. Russol et al (1994) 58, has been reported synthesis of a series of substituted analogues 
based on the novel 4H thieno[2’,3’:4,5]pyrimido [2,1-blbenzothiazole and 4H-
thieno[2׳,3׳:4,5]pyrimido [2,1-blbenzoxazole r&g systems was synthesized.  Synthesized 
compounds were evaluated for their potential analgesic activity in phenylquinone-induced 
writhing test in mice and for their potential antiinflammatory activity in carrageenan-induced rat-
paw oedema test, in acetic-acid peritonitis assay and in cotton oil-induced mouse-ear oedema 
test. 9,10,1 1,12-Tetrahydro-12H benzothieno [2’,3’:4,5]pyrimido [2,l-~]benzoxazol-l2-one (fig 
14) is the most active derivative in the series in all performed tests. It showed remarkable 
analgesic and antiinflammatory activities asspciated with an excellent gastric tolerance. 
                                                 
N
SNS
O
 
Fig 14 
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 14. Venkatesh et al (2009) 59, has been reported a series of some novel 2-amino 
benzothiazole derivatives were synthesized and evaluated for anti-inflammatory activity. The 
anti-inflammatory activities of new compounds were determined by λ-Carrageenan-induced mice 
paw edema method using diclofenac sodium as a standard. Among the compounds tested three 
compounds Bt2 (5- chloro-1,3-benzothiazole-2-amine), and Bt7 (6-methoxy-1,3-benzothiazole-
2-amine) (fig 15) were the most active compounds in these series when compared with 
diclofenac sodium.  
                                                          
S
N
NH2
R= 5Cl Bt2
R= 6-OCH3 Bt7
R
 
Fig 15 
 
15. Muttu et al (2010) 60, has been reported synthesize a series of various substituted 
benzothiazole derivatives containing 7-chloro-6-fluoro-N (substituted hydrozones) - 
benzothiazole. The compounds MIIIc, MIIIf and MIIIJ at dose 5 mg/kg and 10mg/kg body.wt 
were evaluated for anti-inflammatory activity using carragennan induced paw edema method. 
The selected compounds have shown significant anti-inflammatory activity as compared to the 
standard drug. Compound MIIIJ (fig 16) (10 mg/kg body weight) has shown more significant 
result when compared with standard drug. 
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Anthelmentic activity 
16. Sreenivasa M et al (2009) 61 has been reported synthesis of fllurobenzothiazole 
comprising sulfonamide pyrazole derivitives. They screened synthesized for anthelmentic 
activity by using earthworms (Perituma posthum). Albendazole was used as standard drug. The 
compounds were evaluated by time taken for complete paralysis and death of worms. 
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Fig 17 
Anti-diabetic activity 
17. Pattan S et al (2005) 62 has been reported synthesis of 2-amino [5` (4-
sulphonylbenzylidine)-2,4-thiazolidnedione]-7-chloro-6- flurobenzothiazole series and screened 
for their antidiabetic activity on albino rat by alloxan induced tail tipping method. 
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Microsomal triglyceride transfer protein (MTP) inhibitors 
18. Chi B et al (2009) 63 has been reported synthesis of  triamide derivatives based on 
benzothiazoletemplet. A series of these compounds showed potent enterocyte-specific 
microsomal triglyceride transfer protein (MTP) inhibitors. Inhabitation of MTP by small 
molecules, therefore lead to reduction in plasma triglycerides and cholesterol level. 
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Anti alzheimers activity 
19. Serdons K et al (2009)64 has been reported a F-labeled 2-(4′-fluorophenyl)-1-3-
benzothiazoles. They evaluated it as amyloid imaging agent in Alzheimers disease in comparison 
with [11C]PIB (11C labeled 6-hydroxy-2-(4”-N- [11C] methylaminophenol)-1,3-benzothiazole 
and showed excellent characteristics comparable with those of [11C]PIB, namely good affinity 
for amyloid plaques present in human Alzheimers disease. 
                                                             S
N
F
 
Fig 20 
2.2 PYRAZOLONE 
Anti- Mycobacterial Activity 
        20. S.Guniz Kucukgu zel et.al. 65 has been reported Synthesis, characterization of novel 
coupling products and 4-arylhydrazono-2-pyrazoline-5-ones as potential anti-mycobacterial 
agents. Novel coupling products and 4-arylhydrazono-2-pyrazoline-5-ones were synthesized and 
evaluated for anti-mycobacterial activity against Mycobacterium tuberculosis H37Rv and 
Mycobacterium avium. fig 21was found to be the most potent derivatives of the series by an MIC 
value of 6.25µg/ml. 
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Fig 21 
        21. Daniele Castagnolo et.al. 66 has been reported Synthesis, biological evaluation and 
SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis two series 
of pyrazole derivatives were synthesized by parallel solution- phase synthesis and were assayed 
as inhibitors of Mycobacterium tuberculosis (MTB), which is the causative agent of tuberculosis. 
One of these compounds showed high activity against MTB (MIC = 4µg/ml). The newly 
synthesized pyrazoles were also computationally investigated to analyze their fit properties to the 
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pharmacophoric model for anti-tubercular compounds previously built by us and to refine 
structure–activity relationship analysis. The pyrazole derivative, 8g, with the p-bromophenyl 
group at N1 position showed to be very active. 
                                                             
Cl
O
N N
OH
R1
R
8 a-k
Where R= -Br, R1= -CH3. 
Fig 22 
22. Daniele Castagnolo et.al, 67 has done Synthesis, biological evaluation, and SAR 
study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: Part 2. Synthesis 
of rigid pyrazolones. The newly synthesized pyrazolones were also computationally investigated 
to analyze if their properties fit the pharmacophoric model for anti-tubercular compounds 
previously built by us. The results are in agreement with those reported by us previously for a 
class of pyrazole analogues and confirm the fundamental role of the p-chlorophenyl moiety at C4 
in the anti-mycobacterial activity. Compounds 5f–g, bearing N-Me-piperazine and morpholine 
moieties proved to be very active with MIC 4 µg/ml. 
                                                                     
Cl
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5 A-K
 
Fig 23 
                          Where 5f R= -Cl, R1= N-Me-piperazine, 5g R= -Cl R1= Morpholine. 
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Anti- Bacterial Activity 
  23. Amar R. Desai et.al., 68 has been reported microwave induced and conventional 
synthesis of quinazolinones and 3-methyl-1H-5-pyrazolones by Niementowski reaction to 
synthesize 3-substituted/2,3-disubstituted 4(3H) quinazolinones instead of the 2-substituted 
derivatives. All synthesized compounds were screened for their antibacterial activity against 
gram positive and gram negative bacteria and showed good to significant activity, as well as 
antifungal activity against Candida albicans ATCC 10231 and C. krusei GO3. The compounds 
3a, 3b, 3e, 3g and 3h showed significant activity against E.Coli and P. aeruginosa at 100 µg/ml 
concentration. 
                                          
Fig 24 
Anti- Fungal Activity 
  24. R. Venkat Ragavan et.al, 69 has been reported Synthesis of some novel bioactive 4-
oxy/thio substituted-1H-pyrazol-5(4H)-ones via efficient cross-Claisen condensation. α-Oxy/thio 
substituted-β-keto esters were synthesized and converted in situ into 4-oxy/thio substituted-1H-
pyrazol-5(4H)-ones by the addition of hydrazine derivatives and screened for their antibacterial, 
antifungal activities against Aspergillus flavus, Aspergillus fumigates, Candida albicans, 
Penicillium marneffei  and Trichophyton mentagrophytes in DMSO by serial plate dilution 
method and compounds 1a–c, 1e–g, 1i, 1j and 1m–p were active. 
                                                                        
N N
R2
R3
O
X
R1 Fig 25 
Where X    R1      R2       R3 
1a, O -Ph -CH2OPh -H 
LITERATURE REVIEW 
 
DEPT.OF PHARMACEUTICALCHEMISTRY   34 
 
1b, O -Ph -CH2CH3 -H 
1c, O -Ph -CH2OCH3-H. 
 
25. S.Guniz Kucukgu zel et.al. 70 has been described Synthesis, characterization and 
pharmacological properties of some 4-arylhydrazono-2-pyrazoline-5-one derivatives obtained 
from heterocyclic amines compounds were tested in vitro against Gram-positive and Gram-
negative bacterial strains, two mycobacterial strains and a fungus, Candida albicans. Compound 
22 was found to be more active against Staphylococcus aureus than the other compounds at a 
concentration of 15.6μg/ml.  
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 Where Compound 22 R= -C6H5. 
Fig 26 
Anti- Cancer Activity 
26.Magda M.F. Ismail et.al., 71 has been done Synthesis and docking studies of novel 
benzopyran-2-ones with anticancer activity Novel series of 7-substituted-benzopyran-2-ones was 
synthesized by incorporating heterocyclic rings as oxadiazole, triazole, pyrazole or pyrazolin-5-
one to benzopyran-2-one nucleus at p-7 via methylene-oxy (or) acetoxy linker. Among 12, 
compound 9a exhibited broad spectrum antitumor activity showing full panel median growth 
inhibition (GI50) ¼ 5.46 mM. According to docking results using Mol soft ICM 3.4-8c program, 
the target compounds may act through inhibition of topoismerase 1, where camptothecin is used 
as ligand. 
                                    Where Compound 9a R= -ph, R1= -CH3. 
Fig 27 
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  27. Rahat Khan et.al., 72 has been studied Synthesis and preliminary evaluation of 
brominated 5-methyl-2,4-dihydropyrazol-3-one and its derivatives as  cytotoxic agents. The 
cytotoxicity studies of the synthesized compounds revealed that compound 4,4-dibromo-2-(2,4-
dinitro-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-one (2c) had shown tremendous bioactivity 
against brine shrimp. However, the compounds 4,4-dibromo-5-methyl-2,4-dihydro-pyrazol-3-
one (2a),4,4 dibromo-2-(2,4-dibromo-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-one (2b) and  4,4-
dibromo-2-(dinitro-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-one (2c) showed higher activity 
leaving the other compounds almost inactive. 
                                                                      Fig 28 
  28. Xiao Hong Wang et.al., 73 has done A cell based screen for anticancer activity of 13 
pyrazolone derivatives against four human tumour cell lines HepG2, OVCAR3 KB and Multi 
drug resistance (MDR) KBv 200 cell lines invitro and in vivo. The 50% inhibitory concentration 
(IC50) values were determined by MTT assay. Out of 13 compounds screened compound 9 
exhibits remarkable effect of which IC50 values are (3.24± 0.28), (2.58± 0.61), (3.81± 0.02) and 
(3.45 ± 0.03) µg/ml in HepG2, OVCAR3 KB and Multi drug resistance (MDR) KBv 200 cell 
lines respectively (p> 0.05).  
                                                      Fig 29 
 
29. Hari Pado Devnath et.al, 74 has been reported Synthesis of some pyrazolone 
derivatives from ciprofloxacin and study of their cytotoxicity. Three pyrazolone derivatives with 
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pyrazole ring extension were synthesized from ciprofloxacin by treating the parent compound 
with hydrazine derivatives. These derivatives showed potential cytotoxicity against brine shrimp 
nauplii than the ciprofloxacin. The substituted benzene ring by –NO2 group of the 5-
Cyclopropyl-2-(2,4-dinitrophenyl)-8-fluoro-7-piperazin-1-yl-2,5-dihydro pyrazolo [4,3-
c]quinolin-3-one, 1b show better activity than unsubstituted benzene. 
                                         
              Fig 30  Where 1b: R = -C6H3 (NO2)2. 
 
30.G. Mariappan et.al, 75 has been repoted synthesis and bioactivity evaluation of 
pyrazolone derivatives 3-Methyl-4-substituted benzylidene-pyrazol-5-ones are synthesized by 
the condensation of 3-methyl-pyrazol-5-one with substituted aliphatic and aromatic aldehydes. 
Among the synthesized derivatives 5, 6, 7 and 10 are found to have a potent anti-inflammatory 
response whereas compounds 1, 4, 5, 8 and 10 have an effective analgesic response. There is no 
remarkable difference in bioactivity of pyrazolones derived from aliphatic and aromatic  
aldehydes. 
                                                 
N
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H
R
 Where, R= 3-Cl. 
Fig 31 
Non steroidal anti-inflammatory activity 
  31.Soad A.M. El-Hawash et.al., 76 has been prepared “Non steroidal anti-inflammatory 
agents—part 2 anti-inflammatory, analgesic and antipyretic activity of some substituted 3-
pyrazolin-5-ones and 1,2,4,5,6,7-3H-hexahydroindazol-3-ones.” Anti-inflammatory, analgesic 
and antipyretic activities recorded for some of new 3-pyrazolin-5-ones. A structure–activity 
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relationship (SAR) comparative study indicated that some compounds from 3-pyrazolin-5-one 
(2, 6–8, 10) series exhibited pronounced anti-inflammatory, analgesic and antipyretic activities 
relative to indomethacin. 
                                      
Fig 32 
  32.Amol Gadakh et.al., 77 has been described an efficient synthesis of 3-trifluoro 
methyl-1-(3,4-difluorophenyl)-1H-pyrazol-5(4H)-one(3) and their Knoevenagel condensation 
reaction with 1,4-diphenyl -1H-pyrazole-3-carbaldehydes  4,4-oxo-4H-chromene-3-
carbaldehydes and 2-chloro quinoline-3-carbaldehydes have been described by using 
conventional and non-conventional techniques. Comparison of conventional and non-
conventional techniques like Microwave , Ultrasonic  assisted reactions showed that, the later 
procedure require shorter reaction time, good yield and was applicable for larger set of substrates 
emphasizing the importance of eco-friendly conditions. 
                                  
Fig 33 
  33.Angela antochi et.al, 78 has been studied the synthesis and modelling of the obtaining 
process of 1-[2’-(theophyllin-7-yl) sulfonyl-4-chlor-phenoxyacetyl]-3-methyl-5-pyrazolone 
starting from 4-chlor-2-(theophyllin-7’-yl)sulfonyl-phenoxyacetyl  hydrazide and concluded the 
optimum reaction time is 18.35 hours. The optimum ratio of the reactants hydrazide and ethyl 
acetoacetate is of 1/2.49 and the output for 1-[2’-(theophyllin-7-yl) sulfonyl-4-chlor-
phenoxyacetyl]-3-methyl-5-pyrazolone tends toward optimum when all the considered variables 
remain in the limits of the initially established variation domain. 
LITERATURE REVIEW 
 
DEPT.OF PHARMACEUTICALCHEMISTRY   38 
 
                                            
Fig 34 
  34.Mohamed A. Saleh et.al., 79 has been reported Synthesis of Novel 3H-Quinazolin- 4-
ones Containing Pyrazolinone, Pyrazole and Pyrimidinone Moieties from the diazonium salt of 
3-(4-aminophenyl)-2-methyl-3H-quinazolin-4-one and its 6-bromo derivative reacted with some 
active methylene compounds, namely ethyl aceto acetate, ethyl cyano acetate and acetyl acetone, 
to afford the corresponding hydrazono quinazolinone derivatives ant they are tested for Non 
steroidal anti-inflammatory activity.     
                                                                                            
 fig 35 
Where Compound 9a R = H, X = H, 9b R = H, X = Br, 9c R = Ph, X = H, 9d R = Ph, X =Br. 
 
  35.Ruoqun Ma et.al. 80 has been developed An efficient one-pot method to generate 
structurally diverse and medicinally interesting pyrazolone derivatives in good to excellent yields 
of 51–98% under microwave irradiation and solvent-free conditions. 4-arylidenepyrazolone 
derivatives 1 are synthesized using as starting materials substituted aldehydes 5 or imine and 2-
pyrazolin-5-ones 4, the latter generally being obtained by the Knorr condensation of β-ketoesters 
2 with substituted hydrazines 3. 
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                           fig 36 
 
2.3 Mannich Bases 
  36.Sheela Joshi et.al., 81 has been reported “In vitro study of some medicinally important 
Mannich bases derived from anti-tubercular agent”, Biologically active Mannich bases with 
heteroaromatic ring system have been synthesised employing Mannich reaction of isonicotinyl 
hydrazide with various sulphonamides/secondary amines and Comparing antibacterial activity of 
newly synthesized Mannich bases with sulphonamides observed that Mannich (Fig 37) is 
significantly better than its corresponding sulphonamide in checking the growth of P. multocida. 
                                            
                                                     R= -COCH3Na (H2O). Fig 37 
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Since resistance of pathogenic bacteria towards available antibiotics is rapidly becoming 
a major worldwide problem, the design of new compounds to deal with resistant bacteria has 
become one of the most important areas of anti-microbial research today.  
During the past decades, large numbers of therapeutic agents are synthesized with the 
help of benzothiazole nucleus because of their pharmacological properties such as anti- 
microbial2, anti-tumor3, anti-tubercular4, immunosuppressive5, anti-convulsant6, anti-
inflammatory7, anti-diabetic8,  etc,.  
Moreover, the benzothiazole structure containing sulphur and nitrogen in five membered 
ring systems which is similar to that of first anti-microbial agent penicillin and its derivatives 
ring system. 
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Fig. 3.1 
The literature review shows that many researchers have synthesised 2-substituted 
benzothiaozle as a target structure and evaluated its biological activities. e.g. 
1. Barot Hitesh.k.et.al., (2010)54 has been reported synthesis and characterisation of 
various substituents of 2-amino-7-chloro-6-fluoro benzothiazole. The results suggest that 
among the compounds tested 2-(2-(3,4,5-trimethoxybenzylidene)hydrazinyl)-N,N-2-
hydroxydiethyl-6-fluorobenzo[d]thiazol-7-amine (fig 3.2) have exhibited higher activity 
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Fig. 3.2 
2. Roman lesyk.et.al., (2010)50 has been reported the anti-cancer activity of 
(benzothiazole-2-yl) hydrazine with trithiocarbonyl diglycolic acid or 6-methyl-2-
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aminobenzothiazole with 2-carbethoxymethylthio-4-one have yielded starting 3- or 2-
substituted 4-thiazolidiones. 
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Fig. 3.3 
           On the other hand, pyrazolone derivatives have engrossed substantial attention from 
organic and medicinal chemists for many years as they belong to a class of compounds with 
proven utility in medicinal chemistry. Antipyrine was the first pyrazolone derivative   for 
management of pain inflammation and fever. In addition, many pyrazolone derivatives have 
special ability to scavenger reactive oxygen species (ROS) and to influence processes involve 
in free radical injury, large numbers of therapeutic agents are synthesized with the help of 
pyrazolone nucleus because of their pharmacological properties anti-microbial34, anti-
cancer35, anti-inflammatory36, analgesic36, anti-pyretic36, anti-bacterial37, anti-tubercular38 , 
anti-oxidant activities, etc,. 
The literature review shows that many researchers have synthesised pyrazolone 
derivatives as a target structure and evaluated its biological activities. e.g. 
1. S. Guniz Kucukgu et.al., 65 has been reported Synthesis, characterization of novel     
coupling products and 4-arylhydrazono-2-pyrazoline-5-ones and screened for their anti-
mycobacterial against Mycobacterium tuberculosis H37Rv and Mycobacterium avium.  
                                
NH
N
N
N
O
H3C
N
HN
N
S
CH3  
Fig. 3.4 
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2. Soad A.M. El-Hawash et.al., 76 has been reported synthesis and  anti-inflammatory, 
analgesic and antipyretic activity of some substituted 3-pyrazolin-5-ones and 1,2,4,5,6,7-3H-
hexahydroindazol-3-ones 
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Fig. 3.5 
From the above literatures, some of the compounds bearing the pharmacophore 
groups showed in the fig 3.6 have been reported to responsible for anti-microbial activity and 
anti-cancer activity moreover the pyrazolone has been reported as anti-oxidant properties. 
With this background the aim of our present study is to couple benzothiazole and pyrazolone 
through azomethine protons (-NHN=CH) linkage to constitute important new class of 
compound, have potent anti-microbial, anti-oxidant properties with less side effects.   
 
THE PROPOSED STRUCTURE 
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Fig. 3.6 
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The plan of the present work can be summarized as follows: 
 
 Literature review and scheme development. 
 To synthesis some novel Benzothiazole nucleus containing pyrazolone, having active 
hydrogen in 2nd position (NH) and subject to N-Mannich reaction to form title 
compounds.  
 To determine physicochemical properties of synthesized compounds by Melting point, 
TLC and solubility. 
 Characterization of synthesized compounds by various analytical techniques like UV, IR 
1HNMR and Mass Spectral studies. 
 Screening of synthesized compounds for their in-vitro anti-microbial activity against 
gram positive and gram negative bacteria and fungal by Disc diffusion method and 
determination of Minimum inhibitory concentration (MIC) by 2-fold serial dilution 
method.  
 Screening of synthesized compounds for their in-vitro anti-oxidant property by DPPH, 
FRAP and ABTS methods 
 Screening of synthesized compounds for in-vitro cytotoxic activity by MTT assay 
method. 
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DETERMINATION OF PHYSICOCHEMICAL PROPERTIES OF 
SYNTHESIZED COMPOUNDS 
 
MELTING POINT ANALYSIS  
Melting points of the synthesized compounds were determined in a one end fused capillary 
tube method by using Thermionic Model–C-LMP- 1 CAMPVEEL Serial. No. 0712022 melting 
point apparatus, and were uncorrected. 
 
THIN LAYER CHROMATOGRAPHY ANALYSIS82 
Purity of the compounds was checked by TLC using silica gel G (0.5mm thickness) coated 
over glass plate (12 x 20 cm). For the determination Rf value the dried silica gel G coated over 
glass plate were used.  
Preparation of TLC plate: By using distilled water silica gel G slurry is prepared and poured 
on to a glass plate which is maintained on a level surface. The slurry is spread uniformly on the 
surface of the glass plate. After setting, the plates are dried in an oven at 50˚C or 15 minutes for 
activating the TLC plate 
Chromatogram was developed by ascending technique when solvent front travelled 
appropriate distance; plates were taken out and dried. The location of spot was detected by 
using iodine chamber.  
Rf = Distance travelled by solute / Distance travelled by solvent 
 
SOLUBILITY83 
Solubility the solubility of synthesised compound was tested in different solvents such as 
polar, semi polar, and non polar solvents. 
Polar solvent: A solvent in whose molecules there is either a permanent separation of 
positive and negative charges, or the centres of positive and negative charges do not coincide; 
these solvents have high dielectric constants, are chemically active, and form coordinate 
covalent bonds; examples are water and carboxylic acids etc.  
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Semi polar solvent: Semi-polar solvents may induce a certain degree of polarity in non-
polar molecules and may thus act to improve the miscibility of polar and non-polar liquids; 
examples are alcohols and ketones etc. 
        nonpolar solvent: a liquid solvent without significant partial charges on any atoms, as in the 
hydrocarbons, or where the polar bonds are arranged in such a way that the effects of their partial 
charges cancel out, as in carbon tetrachloride. Liquid hydrocarbons are the most common 
examples. 
The following table 5.1 indicates the meanings of the terms used in statements of 
approximate solubilities. 
 
 
Table: 5.1 
 
Descriptive  term Approximate volume of solvent 
in millilitres per gram of solute 
Very soluble less than 1 
Freely soluble from 1-10 
Soluble from 10-30 
Sparingly soluble from 30-100 
Slightly soluble from 100-1000 
Very slightly soluble from 1000-10,000 
Insoluble or practically insoluble more than 10,000 
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SPECTRAL STUDIES 
CONFIRMATION OF THE STRUCTURE OF SYNTHESIZED COMPOUNDS 
 
ULTRA VIOLET SPECTRAL ANALYSIS 
The maximum absorbance or λmax   of synthesized compounds were determined at 
0.01%w/v concentration in ethanol by using Shimadzu 2000, UV1700 ultraviolet 
Spectrophotometer at KMCH College of pharmacy. The maximum absorbance was measured in 
nm. 
 
INFRARED SPECTRAL ANALYSIS 
The IR Spectra of the synthesized compounds were recorded at KMCH college of pharmacy 
by JASCO-FT/IR -1700, Serial no B016861016 spectrophotometer in KBr disc. The IR value 
was measured in cm-1.  
 
NUCLEAR MAGNETIC RESONANCE SPECTRAL ANALYSIS 
The NMR Spectra of the synthesized compounds were recorded at IIT Madras by Bruker 
300 MHz FT- NMR using TMS (Tetra Methyl Silane) as internal standard. The PMR (Proton 
Magnetic Resonance) spectroscopic values are measured in δ ppm in DMSO-d6. Compounds 
were particulars of work done on DSX-300/AV-III 400/DRX-500/AV-III 500(S)/(L) AV-700 
NMR spectrometer. 
 
MASS SPECTRAL ANALYSIS 
The Mass Spectra of the synthesized compounds were recorded at IIT Madras in MS (EI) 
JEOL GC MATE 700 EV. 
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METHODOLOGY 
Step I: Synthesis of 6-bromobenzo[d]thiazol-2-amine (BTZ) 84 
To glacial acetic acid (150ml), precooled to 5˚C, ammonium thiocyanate (0.06 mol, 
4.56gm) and 4-bromoaniline (0.06mol, 10.26gm) were added. The mixture was placed in dry ice 
then addition of bromine (0.02mol, 1ml of bromine dissolved in 10ml of glacial acetic acid) from 
a dropping funnel at such rate that temperature does not rise above 5˚C, stirring was continued 
for an additional 6 hrs at 0-10˚C and neutralized with aqueous ammonia solution, kept it in 
overnight, filtered, washed with water and dried, recrystallised from ethanol to obtain grey color 
precipitate of 6-bromo benzo [d] thiazol-2-amine (BTZ). The purity of compounds was 
established by single spot on TLC plate. The solvent system used for TLC was chloroform: 
methanol (7:3) and Yield: 95.06%w/w, m.p: 204-206˚C, Rf: 0.786. Table: 5.2. 
 
         
Br NH2
4-bromo aniline
NH4SCN
gla.Acetic acid, Br2
   stirring, 6hrs
          0-10oC
S
N
NH2
Br
6-bromobenzo[d]thiazol-2-amine
 
Step II: Synthesis of Ethyl [2-(6-bromo-1, 3-benzothiazol-2-yl) hydraziny 
lidene](cyano)acetate(BTZE) 85 
Dissolve 6-bromo benzo [d] thiazol-2-amine (BTZ) (0.05 mol, 11.45gm) in concen-trated 
HCl (20ml) and water (10 ml), cooled to 0-5˚C under dry ice and precooled solution of sodium 
nitrite (1.5gm in 10ml of water) was added to it dropwise during 10mts. The reaction mixture 
was stirred for 40 minutes. The ice cold mixture of ethyl cyano acetate (0.01mol, 1.12gm) and 
saturated solution of sodium acetate (0.05mol, 4.1gm) in ethanol (50ml), was added dropwise 
with stirring to a solution of diazonium salt compound over 15 mts. The stirring was continued 
for 30 mts at 0-5˚C and the reaction mixture then stirred for 2.30 hrs at room temperature. The 
product was collected and recrystallised from ethanol to give grayish brown color solid of Ethyl 
[2-(6-bromo-1, 3-benzothiazol-2-yl) hydraziny lidene](cyano)acetate (BTZE). The purity of 
compounds was established by single spot on TLC plate. The solvent system used was benzene: 
chloroform: water (40:35:25) and Yield: 58.07%w/w, m.p: 174-176˚C, Rf: 0.446. Table: 5.2 
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S
N
NH2
Br
6-bromobenzo[d]thiazol-2-amine
S
N
H
N
Br
N
CN
COOC2H5
CNCH2COOCH2CH3
CH3COONa
NaNO2/HCl
0-5oC
stirring 2.30 hrs
ethyl [2-(6-bromo-1,3-benzothiazol-2-
yl)hydrazinylidene](cyano)acetate  
Step III: Synthesis of 5-amino-4-[2-(6-bromo-1, 3-benzothiazol-2-yl) hydra 
-zinylidene]-2, 4-dihydro-3H-pyrazol-3-one (BTZP) 85 
A mixture of ethyl cyano[2-(4-phenyl-1,3-thiazol-2-yl)hydrazinylidene]acetate, 
(0.005mole, 1.5gm) and hydrazine hydrate (0.01 mole, 0.32ml) in 30 ml of ethanol was heated 
under reflux for 6 hrs. The solvent was concentrated and the product obtained was allowed to 
cool, filtered, washed with water, dried and recrystallized from ethanol to get brownish red 
colour solid of 5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinyl-idene]-2,4-dihydro-
3H-pyrazol-3-one(BTZP). The purity of compounds was established by single spot on TLC 
plate. The solvent system used for TLC was benzene: chloroform: water (40:35:25) and Yield: 
67%w/w, m.p: 211-213˚C, Rf: 0.685 Table: 5.2. 
S
N H
N
Br
N
CN
COOC2H5
ethyl [2-(6-bromo-1,3-benzothiazol-2-yl)
hydrazinylidene](cyano)acetate
NH2NH2. H2O
C2H5OH
Reflux on water bath
             6 hrs
60oC
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NH2
5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydra
-zinylidene]-2,4-dihydro-3H-pyrazol-3-one  
Step IV: Synthesis of Mannich Bases81 
     A mixture of 5-amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydra-zinylidene]-2,4-
dihydro-3H-pyrazol-3-one (0.05 mole, 1.73 gm) and 90% formaldehyde (6 ml) were refluxed 
with different  aromatic amines (0.1mole) in ethanol (30 ml)  for appropriate time and the 
reaction was monitored by TLC. The resulting mixture was poured in to crushed ice. The solid 
obtained was filtered, dried and recrystalized from ethanol. The physicochemical properties and 
the synthesized compounds were given in the Table: 5.4. 
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SCHEME 
+ NH4SCN
S
N
NH2
Br
CNCH2COOCH2CH3
CH3COONa NaNO2/HCl
0-5oC
4-Bromobenzenamine Ammonium thiocyanate
S
N
NH
N
CN
O
Br
O
C2H5
Ethyl [2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene](cyano)acetate
S
N
NH
Br
N
N
H
N
O
NH2
5-Amino-4-[2-(6-bromo-1,3-benzothiazol-2-yl)hydrazinylidene]-2,4-dihydro-3H-pyrazol-3-one
6-Bromo-1,3-benzothiazol-2-amine
Br2
Glacial CH3COOH
0-5oC
Stirring for 6 hrs
NH2NH2. H2O
C2H5OH
Stirring 2.30 hrs
Reflux on water bath 6 hrs
NH2Br
90%  HCHO
C2H5OH
Reflux on water bath 4-6 hrs
                  60oC
MANNICH BASE
S
N
NH
Br
N
N
NO
NH2
H2C R
60oC
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LIST OF AMINES USED IN MANNICH BASE 
 
H
N OH
H
N COOH
H
N OCH3
4-amino phenol
4-amino benzoicacid
4-methoxy aniline
H
N Br
4-bromo aniline
H
N Cl
4-chloro aniline
H
N N N
4-amino azo benzene
H
N
O2N
2-nitro aniline
H
N
H3C
2-methyl aniline
N
H N
S
H
N
N
2-amino pyridine
R=
1
2
3
4
5
7
8
10
12
Br
H
N
Cl
2-chloro aniline
6
H
N
4-nitro aniline
NO2
9
11
6-bromobenzo[d]thiazol-2-amine  
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Table: 5.2 PHYSICOCHEMICAL PROPERTIES OF INTERMEDIATES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cpd 
code 
Molecular 
formula 
Molecular 
weight 
Rf 
Value 
Melting 
point ˚C 
CLog P Polarizability Percentage    
Yield 
 
BTZ 
 
C7H5BrN2S 
 
229 
 
0.78 
 
204-206 
 
2.68 
 
19.54 
 
95% 
 
BTZE 
 
C12H9BrN4O2S 
 
353 
 
0.44 
 
174-176 
 
4.78 
 
30.23 
 
57% 
 
BTZP 
 
C10H7BrN6OS 
 
339 
 
0.68 
 
211-212 
 
1.02 
 
28.32 
 
62% 
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Table: 5.3 SPECTRAL DATA OF THE INTERMEDIATES 
 
Cpd    code λmax (IR) υmax (KBr/cm-1) NMR (δ ppm) 
 
BTZ 
 
484 
3573.45 (NH
2
Stretching),  
825.026 (Ar,CH=CHStreching), 
1663.3 (C=NStretching), 
669.178 (C-S-CStreching). 
                            - 
 
BTZE 
 
574 
1527.35 (C=NStretching), 
 1400.07 (C-NStretching), 
 1702.84(COORStretching), 
 3442.31 (-NH-Stretching), 
639.84 (C-S-CStreching). 
6.63(m,3H,Ar) 
6.60(s,1H,NH =N- proton of 
hydrazone) 
3.60(s.3H, -CH3 proton of ethyl) 
 
BTZP 
 
498 
 
3385.00 (NHStreching),  
1676 (C=OStreching),  
1528.38 (C=NStretching),  
3385 (NH2Streching), 
615.43 (C-S-CStreching). 
6.7-6.75(m,3H,Ar) 
6.60(s,1H,NH=N- proton of 
hydrazone) 
7.76(s,1H,NH proton of 
pyrazolone) 
6.55(s,2H,NH2) 
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Table: 5.4     PHYSICOCHEMICAL DATA OF SYNTHESIZED DERIVATIVES 
 
Compound   
code 
Molecular 
formula 
Molecular 
weight 
Rf 
Value
Melting 
point˚C 
CLog P Polarisability %Yield 
B1P C17H14BrN7O2S 460 0.46 209-211 2.53 41.41 95% 
B1PB C18H14BrN7O3S 488 0.44 189-191 3.28 43.20 72% 
B1M C18H16BrN7O2S 474 0.72 219-221 3.30 43.30 72% 
B1Br C17H13Br2N7OS 523 0.66 229-231 4.36 43.69 75% 
B12C C17H13BrClN7OS 478 0.74 250-251 4.21 42.69 72% 
B14C C17H13BrClN7OS 478 0.46 219-221 4.21 42.68 72% 
B1AZ C23H18BrN9OS 548 0.71 240-242 5.69 51.94 69% 
B12N C17H13BrN8O3S 489 0.56 239-241 3.74 42.78 77% 
B14N C17H13BrN8O3S 489 0.43 220-222 3.59 42.77 71% 
B1AP C16H13BrN8OS 445 0.46 221-223 2.67 39.91 72% 
B1T C18H16BrN7OS 458 0.72 261-263 3.69 42.50 73% 
B1B C18H12Br2N8OS2 580 0.58 190-192 5.05 48.97 77% 
 
Solubility: partially soluble in ethanol 
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Table: 5.5 SPECTRAL DATA OF THE SYNTHESIZED COMPOUNDS  
S
N
NH
N
N
N
H2N
O
Br
CH2 R
 
 
Cpd 
Code 
R λmax 
(nm) 
(IR) υmax (KBr/cm-1) NMR (δ ppm) Molecular ion   (m/z) 
 
B1P 
 
H
N OH
 
 
784 
 
1. 1587.7(C=N), 
2.  832.13 (Ar,CH=CH), 
3. 1598.7(C=O), 
4. 3141.47(NH aliphatic), 
5. 1165.76 (OH), 
6. 636.53 (C-Br). 
6.60(s,1H,NH=N-proton of hydrazone) 
4.8 (d, -CH2- methylene),  
7.5-7.7 (m, Ar- H), 
6.63(s,2H,NH2), 
9.1(s,1H,OH). 
 
- 
 
B1PB 
 
H
N COOH
 
   
594 
 
1. 1588.09(C=N), 
2. 808.02(Ar, CH=CH), 
3. 3127.01(COOH), 
4. 691.35(C-Br).  
6.62(s,1H,NH=N-proton of hydrazone)
7.78-8.04 (m, Ar-H), 
6.92(s,2H,NH2), 
4.72 (d, -CH2- methylene),  
 
 
 
- 
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Cpd code R λmax 
(nm) 
(IR) υmax (KBr/cm-1) NMR (δ ppm) Molecular ion 
(m/z) 
 
B1M 
 
 
H
N OCH3
 
 
487 
 
1. 1526.33(C=N), 
2. 862.02 (Ar,CH=CH), 
3. 3118.33( NH aliphatic), 
4. 675.92 (C-Br).  
6.63(s,1H,NH=N-proton of 
hydrazone), 
3.3(s,3H,(OCH3), 
7.73-8.14 (m, Ar-H), 
6.73(s,2H,NH2), 
4.8 (d, -CH2- methylene),  
 
 
- 
 
B1Br 
 
H
N Br
 575 
1. 1660.63(C=N) 
2. 768.49(Ar CH=CH), 
3. 3121.22( NH aliphatic) 
4. 1674.87 (C=O), 
5. 676.17 (C-Br). 
6.90(s,1H,NH=N-proton of 
hydrazone), 
7.5-7.7 (m, Ar-H), 
6.7(s,2H,NH2), 
4.95 (d, -CH2- methylene),  
 
 
- 
 
B12C 
 
H
N
Cl  
564 
 
1.   697.12(ArCH=CH),  
2.  1676.8 (C=O),          
3.  771.38 (C-Cl). 
6.60(s,1H,NH=N-proton of 
hydrazone), 
8.00 (m, Ar-H), 
4.7(s,2H,NH2), 
4.9 (d, -CH2- methylene),  
 
 
- 
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Cpd Code 
 
R λmax 
(nm) 
(IR) υmax (KBr/cm-1) NMR (δ ppm) Molecular ion   (m/z) 
 
B14C 
 
     
H
N Cl
 
518 
1.  775.24(ArCH=CH),   
2   1676.80 (C=O), 
3.  697.01 (C-Cl). 
6.40(s,1H,NH=N-proton of 
hydrazone), 
7.04-7.64 (m, Ar-H), 
6.5(s,2H,NH2), 
4.62 (d, -CH2- methylene),  
 
478.75 
Base peak 
478.47 
 
 
 
B1AZ 
 
H
N N N
 
 
 
439 
 
1. 1491 (C=N), 
2. 830.20(Ar,CH=CH), 
3. 3363.25( NH aliphatic), 
4. 1655.60 (C=O), 
 
6.80(s,1H,NH=N-proton of 
hydrazone), 
7.83-8.0 (m, Ar-H), 
4.72 (d, -CH2- methylene),  
 
 
548.42 
Base peak 
548.50 
 
B12N 
 
H
N
O2N  
 
 
729 
 
1. 1669.09 (C=N), 
2. 840.81(Ar, CH=CH), 
3. 1603.52 (C=O), 
4. 3359.39( NH aliphatic),  
5. 1510.95 (-NO2). 
6.63(s,1H,NH=N-proton of 
hydrazone), 
7.78-8.02 (m, Ar-H), 
6.67(s,2H,NH2), 
4.82 (d, -CH2- methylene),  
 
- 
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Cpd Code 
 
R λmax 
(nm) 
(IR) υmax (KBr/cm-1) NMR (δ ppm) Molecular ion   (m/z) 
 
B14N 
 
H
N NO2
 
 
654 
1.   1669.09 (C=N), 
2.   840.81 (Ar, CH=CH), 
3.   1603.52 (C=O), 
4.   3359.39.04( NH aliphatic),  
5.   1510.95 (-NO2). 
6.60(s,1H,NH=N-proton of 
hydrazone), 
7.73-8.14 (m, Ar-H), 
 
- 
 
 
B1AP 
 
H
N
N  
 
 
498 
1. 1593.6 (C=N), 
2. 843.42 (Ar CH=CH), 
3. 1671 (C=O), 
 
6.56(s,1H,NH=N-proton of 
hydrazone), 
7.78-8.04 (m, Ar-H), 
6.53(s,2H,NH2), 
4.72 (d, -CH2- methylene),  
 
- 
 
 
B1T 
 
H
N
H3C  
 
 
474 
 
1.    926.54(Ar CH=CH), 
2.   1674.87 (C=O), 
3.   1600.63 (C=N), 
4.   1293.36 (C-CH3) 
6.5(s,1H,NH=N-proton of 
hydrazone), 
7.7-7.8 (m, Ar-H), 
6.6 (s,2H,NH2), 
4.7 (d, -CH2- methylene),  
3.5(s, -CH3) 
 
 
458.33 
Base peak 
458.99 
 
B1B 
 
HN
N
S
Br
 
 
 
483 
 
1. 1511.11 (C=N), 
2. 3390.00( NH aliphatic), 
3. 1673.91(C=O), 
4. 686.17 (C-BrStreching), 
 
6.9(s,1H,NH=N-proton of 
hydrazone), 
7.78-8.04(m,ArH), 
6.93(s,2H,NH2), 
4.72 (d, -CH2- methylene),  
 
 
580.28 
Base peak 
580.28 
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IR Spectra of compounds 
 
 Compound BTZ 
 
 Compound BTZE 
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 Compound BTZP 
 
 
 
 
 
 Compound B1P 
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 Compound B1PB 
 
 
 Compound B1M 
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 Compound B1Br 
 
 
 
 
 
 
 Compound B12C 
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 Compound B14C 
 
 
 
 
 
 
 Compound B1AZ 
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 Compound B12N 
 
 
 
 
 
 
 Compound B14N 
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 Compound B1AP 
 
 
 
 
 
 
 Compound B1T 
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 Compound B1B 
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 NMR SPECTRUM 
 Compound BTZE 
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 Compound BTZP 
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 Compound B1P 
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EXPERIMENTAL WORK 
 
DEPT. OF PHARMACEUTICAL CHEMISTRY   72 
 
 
 
 
 Compound B1PB 
 
 
EXPERIMENTAL WORK 
 
DEPT. OF PHARMACEUTICAL CHEMISTRY   73 
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 Compound B1M 
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 Compound B1Br 
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 Compound B14C 
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 Compound B1AZ 
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 Compound B12N 
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 Compound B1AP 
 
 
 
 
 
EXPERIMENTAL WORK 
 
DEPT. OF PHARMACEUTICAL CHEMISTRY   84 
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 Compound B1T 
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 Compound B1B 
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 MASS SPECTROGRAM 
 Compound B1AZ 
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 Compound B1B 
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 Compound B1T 
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 Compound B14C 
 
 
 
